Cyclin	Cyclin	NNP	O
-	-	HYPH	O
dependent	dependent	JJ	O
kinases	kinase	NNS	O
are	be	VBP	O
the	the	DT	O
family	family	NN	O
of	of	IN	O
Ser	Ser	NNP	O
/	/	SYM	O
Thr	Thr	NNP	O
protein	protein	NN	O
kinases	kinase	NNS	O
that	that	WDT	O
are	be	VBP	O
essential	essential	JJ	O
in	in	IN	O
regulating	regulate	VBG	O
cell	cell	NN	O
progression	progression	NN	O
through	through	IN	O
cell	cell	NN	O
cycle	cycle	NN	O
G	g	NN	O
/	/	SYM	O
S	S	NNP	O
and	and	CC	O
G2	G2	NNP	O
/	/	SYM	O
M	M	NNP	B
.	.	.	O

The	the	DT	O
activities	activity	NNS	O
of	of	IN	O
cyclin	cyclin	NN	O
-	-	HYPH	O
dependent	dependent	JJ	O
kinases	kinase	NNS	O
are	be	VBP	O
regulated	regulate	VBN	O
by	by	IN	O
the	the	DT	O
regulatory	regulatory	JJ	O
subunits	subunit	NNS	O
of	of	IN	O
the	the	DT	O
complex	complex	JJ	O
cyclins	cyclin	NNS	O
and	and	CC	O
phosphorylation	phosphorylation	NN	O
.	.	.	O

Cyclin	Cyclin	NNP	O
E	E	NNP	O
binds	bind	NNS	O
G1	g1	NN	O
phase	phase	NN	O
CDK2	CDK2	NNP	O
,	,	,	O
which	which	WDT	O
is	be	VBZ	O
required	require	VBN	O
for	for	IN	O
the	the	DT	O
transition	transition	NN	O
from	from	IN	O
G1	G1	NNP	O
to	to	IN	O
S	S	NNP	O
phase	phase	NN	O
,	,	,	O
while	while	IN	O
binding	bind	VBG	O
with	with	IN	O
Cyclin	Cyclin	NNP	O
A	A	NNP	O
is	be	VBZ	O
required	require	VBN	O
to	to	TO	O
progress	progress	VB	O
through	through	IN	O
the	the	DT	O
S	S	NNP	O
phase	phase	NN	B
,	,	,	B
.	.	.	O

The	the	DT	O
precise	precise	JJ	O
regulation	regulation	NN	O
of	of	IN	O
CDK	CDK	NNP	O
activity	activity	NN	O
is	be	VBZ	O
essential	essential	JJ	O
for	for	IN	O
the	the	DT	O
stepwise	stepwise	JJ	O
execution	execution	NN	O
of	of	IN	O
the	the	DT	O
many	many	JJ	O
processes	process	NNS	O
required	require	VBN	O
for	for	IN	O
cell	cell	NN	O
growth	growth	NN	O
and	and	CC	O
division	division	NN	O
,	,	,	O
including	include	VBG	O
DNA	dna	NN	O
replication	replication	NN	O
and	and	CC	O
chromosome	chromosome	NN	O
separation	separation	NN	B
,	,	,	B
.	.	.	O

Abnormal	abnormal	JJ	O
CDK	CDK	NNP	O
control	control	NN	O
of	of	IN	O
the	the	DT	O
cell	cell	NN	O
cycle	cycle	NN	O
has	have	VBZ	O
been	be	VBN	O
strongly	strongly	RB	O
linked	link	VBN	O
to	to	IN	O
the	the	DT	O
molecular	molecular	JJ	O
pathology	pathology	NN	O
of	of	IN	O
cancer	cancer	NN	O
,	,	,	O
and	and	CC	O
CDK2	CDK2	NNP	O
is	be	VBZ	O
now	now	RB	O
thought	think	VBN	O
to	to	TO	O
be	be	VB	O
dispensable	dispensable	JJ	O
for	for	IN	O
tumour	tumour	NN	O
formation	formation	NN	O
and	and	CC	O
maintenance	maintenance	NN	B
,	,	,	B
.	.	.	O

Additionally	additionally	RB	O
,	,	,	O
increasing	increase	VBG	O
studies	study	NNS	O
have	have	VBP	O
shown	show	VBN	O
that	that	IN	O
inhibition	inhibition	NN	O
of	of	IN	O
CDK2	CDK2	NNP	O
could	could	MD	O
induce	induce	VB	O
cancer	cancer	NN	O
cell	cell	NN	O
apoptosis	apoptosis	NN	O
with	with	IN	O
no	no	DT	O
damage	damage	NN	O
to	to	IN	O
normal	normal	JJ	O
cells	cell	NNS	B
.	.	.	O

Therefore	therefore	RB	O
,	,	,	O
CDK2	CDK2	NNP	O
is	be	VBZ	O
an	an	DT	O
attractive	attractive	JJ	O
target	target	NN	O
for	for	IN	O
the	the	DT	O
development	development	NN	O
of	of	IN	O
a	a	DT	O
novel	novel	JJ	O
anticancer	anticancer	NN	O
agent	agent	NN	B
.	.	.	O

CDK2	CDK2	NNP	O
is	be	VBZ	O
activated	activate	VBN	O
by	by	IN	O
binding	bind	VBG	O
to	to	TO	O
cyclin	cyclin	NNP	O
A.	A.	NNP	O
The	the	DT	O
activation	activation	NN	O
of	of	IN	O
CDK2	CDK2	NNP	O
causes	cause	VBZ	O
a	a	DT	O
change	change	NN	O
in	in	IN	O
the	the	DT	O
conformation	conformation	NN	O
of	of	IN	O
the	the	DT	O
ATP	atp	NN	O
-	-	HYPH	O
binding	bind	VBG	O
region	region	NN	O
.	.	.	O

Researchers	researcher	NNS	O
have	have	VBP	O
designed	design	VBN	O
and	and	CC	O
synthesised	synthesise	VBN	O
a	a	DT	O
large	large	JJ	O
number	number	NN	O
of	of	IN	O
CDK2	CDK2	NNP	O
inhibitors	inhibitor	NNS	O
,	,	,	O
but	but	CC	O
most	most	JJS	O
of	of	IN	O
them	-PRON-	PRP	O
were	be	VBD	O
designed	design	VBN	O
to	to	TO	O
be	be	VB	O
based	base	VBN	O
on	on	IN	O
the	the	DT	O
monomer	monomer	NN	O
structure	structure	NN	O
of	of	IN	O
CDK2	CDK2	NNP	O
.	.	.	O

Although	although	IN	O
some	some	DT	O
of	of	IN	O
these	these	DT	O
inhibitors	inhibitor	NNS	O
such	such	JJ	O
as	as	IN	O
R	R	NNP	O
-	-	HYPH	O
roscovitine	roscovitine	NNP	O
,	,	,	O
SNS-032	SNS-032	NNP	O
,	,	,	O
MK7965	MK7965	NNP	O
,	,	,	O
AT7519	AT7519	NNP	O
and	and	CC	O
R-547	R-547	NNP	O
have	have	VBP	O
entered	enter	VBN	O
clinical	clinical	JJ	O
studies	study	NNS	O
,	,	,	O
they	-PRON-	PRP	O
were	be	VBD	O
terminated	terminate	VBN	O
during	during	IN	O
phase	phase	NN	O
II	ii	CD	O
or	or	CC	O
phase	phase	NN	O
III	iii	CD	O
trials	trial	NNS	O
due	due	JJ	O
to	to	IN	O
unexpected	unexpected	JJ	O
pharmracological	pharmracological	JJ	O
effects	effect	NNS	O
and	and	CC	O
low	low	JJ	O
specificity	specificity	NN	O
resulting	result	VBG	O
in	in	IN	O
off	off	IN	O
-	-	HYPH	O
target	target	NN	O
interactions	interaction	NNS	O
.	.	.	O

Therefore	therefore	RB	O
,	,	,	O
development	development	NN	O
of	of	IN	O
CDK2	CDK2	NNP	O
selective	selective	JJ	O
inhibitiors	inhibitior	NNS	O
would	would	MD	O
be	be	VB	O
valuable	valuable	JJ	O
.	.	.	O

But	but	CC	O
it	-PRON-	PRP	O
is	be	VBZ	O
difficult	difficult	JJ	O
to	to	TO	O
make	make	VB	O
CDK2-specific	CDK2-specific	NNP	O
inhibitors	inhibitor	NNS	O
that	that	WDT	O
do	do	VBP	O
not	not	RB	O
possess	possess	VB	O
affinity	affinity	NN	O
for	for	IN	O
other	other	JJ	O
kinases	kinase	NNS	O
,	,	,	O
especially	especially	RB	O
for	for	IN	O
CDK4	CDK4	NNP	O
.	.	.	O

The	the	DT	O
level	level	NN	O
of	of	IN	O
homology	homology	NN	O
is	be	VBZ	O
64	64	CD	O
%	%	NN	O
between	between	IN	O
CDK2	CDK2	NNP	O
and	and	CC	O
CDK4	CDK4	NNP	O
and	and	CC	O
that	that	DT	O
of	of	IN	O
sequence	sequence	NN	O
identity	identity	NN	O
is	be	VBZ	O
46	46	CD	O
%	%	NN	O
,	,	,	O
which	which	WDT	O
bring	bring	VBP	O
a	a	DT	O
huge	huge	JJ	O
challenge	challenge	NN	O
to	to	TO	O
design	design	VB	O
the	the	DT	O
CDK2	CDK2	NNP	O
selective	selective	JJ	O
inhibitors	inhibitor	NNS	B
.	.	.	O

In	in	IN	O
this	this	DT	O
study	study	NN	O
,	,	,	O
we	-PRON-	PRP	O
introduced	introduce	VBD	O
a	a	DT	O
multistage	multistage	NN	O
virtual	virtual	JJ	O
screening	screening	NN	O
method	method	NN	O
based	base	VBN	O
on	on	IN	O
SVM	SVM	NNP	O
to	to	TO	O
screen	screen	VB	O
the	the	DT	O
CDK2	CDK2	NNP	O
inhibitors	inhibitor	NNS	O
from	from	IN	O
chemical	chemical	NNP	O
database	database	NN	O
NCI	NCI	NNP	O
,	,	,	O
Enamine	Enamine	NNP	O
and	and	CC	O
Pubchem	Pubchem	NNP	O
.	.	.	O

By	by	IN	O
deconstructing	deconstruct	VBG	O
the	the	DT	O
CDK2	CDK2	NNP	O
selective	selective	JJ	O
inhibitors	inhibitor	NNS	O
,	,	,	O
a	a	DT	O
molecular	molecular	JJ	O
descriptor	descriptor	NN	O
model	model	NN	O
based	base	VBN	O
on	on	IN	O
SVM	SVM	NNP	O
would	would	MD	O
be	be	VB	O
trained	train	VBN	O
to	to	TO	O
screen	screen	VB	O
out	out	RP	O
the	the	DT	O
compounds	compound	NNS	O
with	with	IN	O
selective	selective	JJ	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
.	.	.	O

PLIF	plif	JJ	O
pharmacophore	pharmacophore	NN	O
and	and	CC	O
docking	docking	NN	O
methods	method	NNS	O
were	be	VBD	O
introduced	introduce	VBN	O
into	into	IN	O
the	the	DT	O
screening	screening	NN	O
process	process	NN	O
to	to	TO	O
reduce	reduce	VB	O
the	the	DT	O
false	false	JJ	O
positive	positive	JJ	O
rate	rate	NN	O
and	and	CC	O
increase	increase	VB	O
the	the	DT	O
isoform	isoform	NN	O
selectivity	selectivity	NN	B
.	.	.	O

Simultaneously	simultaneously	RB	O
,	,	,	O
molecular	molecular	JJ	O
dynamics	dynamic	NNS	O
and	and	CC	O
binding	bind	VBG	O
free	free	JJ	O
energy	energy	NN	O
calculation	calculation	NN	O
were	be	VBD	O
used	use	VBN	O
to	to	TO	O
verify	verify	VB	O
the	the	DT	O
binding	bind	VBG	O
stability	stability	NN	O
and	and	CC	O
affinity	affinity	NN	O
of	of	IN	O
the	the	DT	O
screened	screen	VBN	O
ligand	ligand	NN	O
to	to	IN	O
CDK2	CDK2	NNP	O
.	.	.	O

All	all	PDT	O
the	the	DT	O
743	743	CD	O
CDK2	CDK2	NNP	O
inhibitors	inhibitor	NNS	O
were	be	VBD	O
collected	collect	VBN	O
from	from	IN	O
The	the	DT	O
Binding	Binding	NNP	O
Database	Database	NNP	O
Target	Target	NNP	O
name	name	NN	O
:	:	:	O
CDK2	CDK2	NNP	O
/	/	SYM	O
Cyclin	Cyclin	NNP	O
A	A	NNP	O
,	,	,	O
671	671	CD	O
from	from	IN	O
Binding	bind	VBG	O
DB	DB	NNP	O
with	with	IN	O
the	the	DT	O
IC50â¤10âÂµM	IC50â¤10âÂµM	NNP	O
,	,	,	O
http://www.bindingdb.org/bind/index.jsp	http://www.bindingdb.org/bind/index.jsp	NNP	O
and	and	CC	O
the	the	DT	O
A	A	NNP	O
Directory	Directory	NNP	O
of	of	IN	O
Useful	Useful	NNP	O
Decoys	Decoys	NNPS	O
database	database	NN	O
,	,	,	O
and	and	CC	O
180	180	CD	O
CDK2	CDK2	NNP	O
non	non	NNS	O
-	-	NNS	O
inhibitors	inhibitor	NNS	O
were	be	VBD	O
collected	collect	VBN	O
from	from	IN	O
the	the	DT	O
Binding	binding	JJ	O
DB	DB	NNP	O
with	with	IN	O
the	the	DT	O
IC50â¥100âÂµM	IC50â¥100âÂµM	NNP	O
.	.	.	O

The	the	DT	O
two	two	CD	O
cut	cut	VBN	O
-	-	HYPH	O
off	off	RP	O
values	value	NNS	O
IC50â¤10âÂµM	IC50â¤10âÂµM	NNP	O
and	and	CC	O
IC50â¥100âÂµM	IC50â¥100âÂµM	NNP	O
will	will	MD	O
minimise	minimise	VB	O
the	the	DT	O
risk	risk	NN	O
of	of	IN	O
including	include	VBG	O
potential	potential	JJ	O
CDK2	CDK2	NNP	O
inhibitors	inhibitor	NNS	O
in	in	IN	O
the	the	DT	O
negative	negative	JJ	O
group	group	NN	O
and	and	CC	O
reduce	reduce	VB	O
the	the	DT	O
number	number	NN	O
of	of	IN	O
false	false	JJ	O
positives	positive	NNS	O
during	during	IN	O
virtual	virtual	JJ	O
screening	screening	NN	O
.	.	.	O

The	the	DT	O
decoys	decoy	NNS	O
were	be	VBD	O
selected	select	VBN	O
so	so	IN	O
that	that	IN	O
they	-PRON-	PRP	O
would	would	MD	O
have	have	VB	O
similar	similar	JJ	O
physical	physical	JJ	O
properties	property	NNS	O
with	with	IN	O
,	,	,	O
but	but	CC	O
be	be	VB	O
chemically	chemically	RB	O
distinct	distinct	JJ	O
from	from	IN	O
CDK2	CDK2	NNP	O
inhibitors	inhibitor	NNS	B
.	.	.	O

In	in	IN	O
detail	detail	NN	O
,	,	,	O
a	a	DT	O
parallel	parallel	JJ	O
strategy	strategy	NN	O
to	to	IN	O
Shoichetâs	shoichetâs	CD	O
and	and	CC	O
Garcia	Garcia	NNP	O
-	-	HYPH	O
Vallveâs	Vallveâs	NNP	O
was	be	VBD	O
applied	apply	VBN	O
to	to	TO	O
develop	develop	VB	O
the	the	DT	O
decoy	decoy	NN	O
sets	set	NNS	O
from	from	IN	O
the	the	DT	O
NCI	NCI	NNP	O
database	database	NN	B
,	,	,	O
PubChem	PubChem	NNP	O
and	and	CC	O
the	the	DT	O
BD	BD	NNP	O
.	.	.	O

First	first	RB	O
,	,	,	O
Tanimoto	tanimoto	NN	O
coefficients	coefficient	NNS	O
between	between	IN	O
a	a	DT	O
set	set	NN	O
of	of	IN	O
651	651	CD	O
known	know	VBN	O
CDK2	CDK2	NNP	O
inhibitors	inhibitor	NNS	O
from	from	IN	O
the	the	DT	O
BD	BD	NNP	O
and	and	CC	O
compounds	compound	NNS	O
to	to	TO	O
be	be	VB	O
sieved	sieve	VBN	O
265,242	265,242	CD	O
from	from	IN	O
the	the	DT	O
NCI	NCI	NNP	O
database	database	NN	O
,	,	,	O
192â845â102	192â845â102	CD	O
from	from	IN	O
PubChem	PubChem	NNP	O
,	,	,	O
and	and	CC	O
compounds	compound	NNS	O
from	from	IN	O
the	the	DT	O
BD	BD	NNP	O
were	be	VBD	O
calculated	calculate	VBN	O
based	base	VBN	O
on	on	IN	O
an	an	DT	O
ECFP	ECFP	NNP	O
similarity	similarity	NN	O
analysis	analysis	NN	B
.	.	.	O

The	the	DT	O
compounds	compound	NNS	O
with	with	IN	O
Tanimoto	Tanimoto	NNP	O
coefficients	coefficient	NNS	O
of	of	IN	O
less	less	JJR	O
than	than	IN	O
0.5	0.5	CD	O
with	with	IN	O
any	any	DT	O
of	of	IN	O
the	the	DT	O
selected	select	VBN	O
CDK2	CDK2	NNP	O
inhibitors	inhibitor	NNS	O
were	be	VBD	O
selected	select	VBN	O
.	.	.	O

Second	second	RB	O
,	,	,	O
the	the	DT	O
five	five	CD	O
physical	physical	JJ	O
properties	property	NNS	O
including	include	VBG	O
molecular	molecular	JJ	O
weight	weight	NN	O
,	,	,	O
number	number	NN	O
of	of	IN	O
hydrogen	hydrogen	NN	O
-	-	HYPH	O
bond	bond	NN	O
donors	donor	NNS	O
and	and	CC	O
hydrogen	hydrogen	NN	O
-	-	HYPH	O
bond	bond	NN	O
acceptors	acceptor	NNS	O
,	,	,	O
number	number	NN	O
of	of	IN	O
rotatable	rotatable	JJ	O
bonds	bond	NNS	O
,	,	,	O
Octanol	Octanol	NNP	O
-	-	HYPH	O
water	water	NN	O
partition	partition	NN	O
coefficient	coefficient	NN	O
logâP	logâp	NN	O
were	be	VBD	O
defined	define	VBN	O
by	by	IN	O
DecoyFinder	DecoyFinder	NNP	O
2.0	2.0	CD	O
for	for	IN	O
the	the	DT	O
CDK2	CDK2	NNP	O
inhibitors	inhibitor	NNS	O
collected	collect	VBN	O
from	from	IN	O
the	the	DT	O
BindingDB	BindingDB	NNP	O
and	and	CC	O
DUD	DUD	NNP	O
.	.	.	O

Then	then	RB	O
,	,	,	O
the	the	DT	O
compounds	compound	NNS	O
in	in	IN	O
NCI	NCI	NNP	O
,	,	,	O
Pubchem	Pubchem	NNP	O
and	and	CC	O
BindingDB	BindingDB	NNP	O
database	database	VBP	O
with	with	IN	O
the	the	DT	O
five	five	CD	O
calculated	calculate	VBN	O
physical	physical	JJ	O
properties	property	NNS	O
similar	similar	JJ	O
to	to	IN	O
any	any	DT	O
of	of	IN	O
the	the	DT	O
CDK2	CDK2	NNP	O
inhibitors	inhibitor	NNS	O
were	be	VBD	O
further	further	RB	O
selected	select	VBN	O
in	in	IN	O
a	a	DT	O
decoys	decoy	NNS	O
dataset	dataset	NN	O
.	.	.	O

Then	then	RB	O
,	,	,	O
10,245	10,245	CD	O
decoys	decoy	NNS	O
from	from	IN	O
NCI	NCI	NNP	O
,	,	,	O
41,250	41,250	CD	O
decoys	decoy	NNS	O
from	from	IN	O
Pubchem	Pubchem	NNP	O
,	,	,	O
and	and	CC	O
114,278	114,278	CD	O
decoys	decoy	NNS	O
from	from	IN	O
BindingDB	BindingDB	NNP	O
were	be	VBD	O
utilised	utilise	VBN	O
to	to	TO	O
build	build	VB	O
the	the	DT	O
training	training	NN	O
and	and	CC	O
independent	independent	JJ	O
validation	validation	NN	O
dataset	dataset	NN	O
.	.	.	O

Finally	finally	RB	O
,	,	,	O
the	the	DT	O
datasets	dataset	NNS	O
included	include	VBD	O
the	the	DT	O
training	training	NN	O
set	set	NN	O
,	,	,	O
test	test	NN	O
set	set	NN	O
70	70	CD	O
positive	positive	JJ	O
compounds	compound	NNS	O
together	together	RB	O
with	with	IN	O
the	the	DT	O
150	150	CD	O
negative	negative	JJ	O
compounds	compound	NNS	O
from	from	IN	O
binding	bind	VBG	O
database	database	NN	O
and	and	CC	O
validation	validation	NN	O
set	set	NN	O
.	.	.	O

First	first	RB	O
,	,	,	O
a	a	DT	O
total	total	NN	O
of	of	IN	O
354	354	CD	O
descriptors	descriptor	NNS	O
for	for	IN	O
the	the	DT	O
training	training	NN	O
compounds	compound	NNS	O
sets	set	NNS	O
were	be	VBD	O
calculated	calculate	VBN	O
using	use	VBG	O
the	the	DT	O
software	software	NN	O
MOE	MOE	NNP	O
2016	2016	CD	O
after	after	IN	O
energy	energy	NN	O
minimisation	minimisation	NN	B
.	.	.	O

Then	then	RB	O
,	,	,	O
the	the	DT	O
GA	GA	NNP	O
-	-	HYPH	O
SVM	SVM	NNP	B
was	be	VBD	O
used	use	VBN	O
to	to	TO	O
select	select	VB	O
optimised	optimise	VBN	O
descriptors	descriptor	NNS	O
.	.	.	O

The	the	DT	O
termination	termination	NN	O
generation	generation	NN	O
number	number	NN	O
was	be	VBD	O
set	set	VBN	O
to	to	IN	O
600	600	CD	O
,	,	,	O
the	the	DT	O
crossover	crossover	NN	O
rate	rate	NN	O
was	be	VBD	O
set	set	VBN	O
to	to	IN	O
0.6	0.6	CD	O
and	and	CC	O
the	the	DT	O
mutation	mutation	NN	O
rate	rate	NN	O
was	be	VBD	O
set	set	VBN	O
to	to	IN	O
0.0033	0.0033	CD	O
.	.	.	O

LIBSVM	LIBSVM	NNP	B
software	software	NN	O
was	be	VBD	O
used	use	VBN	O
to	to	TO	O
establish	establish	VB	O
the	the	DT	O
SVM	SVM	NNP	O
classification	classification	NN	O
model	model	NN	O
based	base	VBN	O
on	on	IN	O
descriptors	descriptor	NNS	O
selected	select	VBN	O
from	from	IN	O
GA	GA	NNP	O
-	-	HYPH	O
SVM	SVM	NNP	O
.	.	.	O

The	the	DT	O
schematic	schematic	JJ	O
hyperplane	hyperplane	NN	O
of	of	IN	O
SVM	SVM	NNP	O
separating	separate	VBG	O
positive	positive	JJ	O
class	class	NN	O
and	and	CC	O
negative	negative	JJ	O
class	class	NN	O
â1	â1	NN	O
with	with	IN	O
the	the	DT	O
maximum	maximum	JJ	O
margin	margin	NN	O
.	.	.	O

All	all	PDT	O
the	the	DT	O
CDK2	CDK2	NNP	O
crystal	crystal	NN	O
structures	structure	NNS	O
were	be	VBD	O
collected	collect	VBN	O
from	from	IN	O
the	the	DT	O
RSCB	RSCB	NNP	O
protein	protein	NN	O
databank	databank	NNP	O
,	,	,	O
the	the	DT	O
proteins	protein	NNS	O
with	with	IN	O
the	the	DT	O
inhibitor	inhibitor	NN	O
in	in	IN	O
the	the	DT	O
ATP	ATP	NNP	O
competitive	competitive	JJ	O
site	site	NN	O
and	and	CC	O
the	the	DT	O
same	same	JJ	O
amino	amino	JJ	O
acid	acid	NN	O
sequence	sequence	NN	O
were	be	VBD	O
aligned	align	VBN	O
over	over	RP	O
for	for	IN	O
putting	put	VBG	O
into	into	IN	O
the	the	DT	O
protein	protein	NN	O
database	database	NN	O
.	.	.	O

The	the	DT	O
interaction	interaction	NN	O
fingerprints	fingerprint	NNS	O
were	be	VBD	O
then	then	RB	O
generated	generate	VBN	O
by	by	IN	O
the	the	DT	O
PLIF	PLIF	NNP	O
Setup	Setup	NNP	O
function	function	NN	O
in	in	IN	O
Database	Database	NNP	O
Viewer	Viewer	NNP	O
panel	panel	NN	O
,	,	,	O
all	all	PDT	O
the	the	DT	O
interactions	interaction	NNS	O
with	with	IN	O
the	the	DT	O
min	min	NNP	O
score	score	NN	O
1	1	CD	O
and	and	CC	O
score	score	NN	O
2	2	CD	O
were	be	VBD	O
0.5âkcal	0.5âkcal	NNP	O
/	/	SYM	O
mol	mol	NN	O
and	and	CC	O
1.5âkcal	1.5âkcal	NNP	O
/	/	SYM	O
mol	mol	NN	O
respectively	respectively	RB	O
.	.	.	O

Then	then	RB	O
,	,	,	O
the	the	DT	O
Query	Query	NNP	O
Generator	Generator	NNP	O
tool	tool	NN	O
was	be	VBD	O
carried	carry	VBN	O
out	out	RP	O
for	for	IN	O
generating	generate	VBG	O
pharmacophore	pharmacophore	NN	O
queries	query	NNS	O
based	base	VBN	O
on	on	IN	O
the	the	DT	O
frequencies	frequency	NNS	O
of	of	IN	O
protein	protein	NN	O
-	-	HYPH	O
ligand	ligand	NN	O
contacts	contact	NNS	O
.	.	.	O

The	the	DT	O
max	max	NNP	O
Radius	Radius	NNP	O
was	be	VBD	O
set	set	VBN	O
to	to	IN	O
3	3	CD	O
,	,	,	O
the	the	DT	O
Feature	Feature	NNP	O
Coverage	Coverage	NNP	O
was	be	VBD	O
set	set	VBN	O
to	to	IN	O
25%-75	25%-75	CD	O
%	%	NN	O
,	,	,	O
Excluded	Excluded	NNP	O
Volumes	Volumes	NNP	O
was	be	VBD	O
set	set	VBN	O
to	to	IN	O
ON	ON	NNP	O
,	,	,	O
other	other	JJ	O
parameters	parameter	NNS	O
were	be	VBD	O
kept	keep	VBN	O
at	at	IN	O
their	-PRON-	PRP$	O
default	default	NN	O
values	value	NNS	O
.	.	.	O

The	the	DT	O
Genetic	Genetic	NNP	O
Optimisation	Optimisation	NNP	O
of	of	IN	O
Ligand	Ligand	NNP	O
Docking	Docking	NNP	O
module	module	NN	O
in	in	IN	O
MOE2016	MOE2016	NNP	O
software	software	NN	O
was	be	VBD	O
used	use	VBN	O
to	to	TO	O
perform	perform	VB	O
the	the	DT	O
molecular	molecular	JJ	O
docking	docking	NN	O
study	study	NN	O
and	and	CC	O
analyse	analyse	VB	O
the	the	DT	O
interaction	interaction	NN	O
between	between	IN	O
the	the	DT	O
ligand	ligand	NN	O
and	and	CC	O
receptor	receptor	NN	B
,	,	,	B
.	.	.	O

The	the	DT	O
targeted	targeted	JJ	O
protein	protein	NN	O
was	be	VBD	O
corrected	correct	VBN	O
,	,	,	O
protonated	protonate	VBN	O
,	,	,	O
tethered	tether	VBD	O
,	,	,	O
and	and	CC	O
stage	stage	NN	O
minimised	minimise	VBN	O
by	by	IN	O
QuickPrep	QuickPrep	NNP	O
function	function	NN	O
in	in	IN	O
MOE	MOE	NNP	O
panel	panel	NN	O
:	:	:	O
the	the	DT	O
Structure	Structure	NNP	O
,	,	,	O
Protonate3D	protonate3d	JJ	O
and	and	CC	O
ASN	ASN	NNP	O
/	/	SYM	O
GLN	GLN	NNP	O
/	/	SYM	O
HIS	his	PRP$	O
Filps	filp	NNS	O
were	be	VBD	O
set	set	VBN	O
to	to	IN	O
on	on	IN	O
and	and	CC	O
the	the	DT	O
water	water	NN	O
farther	farther	RB	O
than	than	IN	O
4.5âÃ	4.5âã	CD	O
from	from	IN	O
Ligand	Ligand	NNP	O
or	or	CC	O
receptor	receptor	NN	O
were	be	VBD	O
deleted	delete	VBN	O
.	.	.	O

The	the	DT	O
binding	bind	VBG	O
pocket	pocket	NN	O
was	be	VBD	O
defined	define	VBN	O
near	near	IN	O
the	the	DT	O
ATP	ATP	NNP	O
-	-	HYPH	O
competitive	competitive	JJ	O
site	site	NN	O
within	within	IN	O
6.0âÃ	6.0âã	CD	O
to	to	TO	O
make	make	VB	O
sure	sure	JJ	O
that	that	IN	O
the	the	DT	O
space	space	NN	O
was	be	VBD	O
large	large	JJ	O
enough	enough	RB	O
for	for	IN	O
accommodating	accommodate	VBG	O
the	the	DT	O
ligand	ligand	NN	O
scale	scale	NN	B
.	.	.	O

During	during	IN	O
the	the	DT	O
case	case	NN	O
of	of	IN	O
selecting	select	VBG	O
function	function	NN	O
scores	score	NNS	O
,	,	,	O
50	50	CD	O
inhibitors	inhibitor	NNS	O
with	with	IN	O
IC50	IC50	NNP	O
values	value	NNS	O
were	be	VBD	O
docked	dock	VBN	O
into	into	IN	O
the	the	DT	O
binding	bind	VBG	O
pocket	pocket	NN	O
by	by	IN	O
using	use	VBG	O
GoldScore	GoldScore	NNP	O
,	,	,	O
ChemScore	ChemScore	NNP	O
,	,	,	O
ASP	ASP	NNP	O
and	and	CC	O
PLP	PLP	NNP	O
function	function	NN	O
score	score	NN	O
,	,	,	O
DCG	DCG	NNP	O
algorithm	algorithm	NNP	O
to	to	TO	O
examine	examine	VB	O
the	the	DT	O
consistency	consistency	NN	O
between	between	IN	O
the	the	DT	O
experimental	experimental	JJ	O
IC50	IC50	NNP	O
and	and	CC	O
different	different	JJ	O
score	score	NN	O
functions	function	NNS	O
.	.	.	O

The	the	DT	O
reli	reli	NN	O
refers	refer	VBZ	O
to	to	IN	O
the	the	DT	O
pIC50	pic50	NN	O
and	and	CC	O
the	the	DT	O
IDCG	IDCG	NNP	O
refers	refer	VBZ	O
to	to	IN	O
the	the	DT	O
ordered	order	VBN	O
IC50	IC50	NNP	O
values	value	NNS	O
.	.	.	O

The	the	DT	O
closer	close	RBR	O
the	the	DT	O
Normalised	Normalised	NNP	O
Discounted	discount	VBN	O
Cumulative	Cumulative	NNP	O
Gain	Gain	NNP	O
value	value	NN	O
is	be	VBZ	O
to	to	IN	O
1	1	CD	O
,	,	,	O
the	the	DT	O
better	well	JJR	O
the	the	DT	O
consistency	consistency	NN	O
between	between	IN	O
the	the	DT	O
IC50	IC50	NNP	O
and	and	CC	O
function	function	NN	O
score	score	NN	O
is	be	VBZ	O
.	.	.	O

Finally	finally	RB	O
,	,	,	O
the	the	DT	O
selected	select	VBN	O
function	function	NN	O
score	score	NN	O
was	be	VBD	O
used	use	VBN	O
to	to	TO	O
evaluate	evaluate	VB	O
the	the	DT	O
affinity	affinity	NN	O
between	between	IN	O
the	the	DT	O
ligand	ligand	NN	O
and	and	CC	O
compounds	compound	VBZ	B
.	.	.	O

NDCGP	NDCGP	NNP	O
=	=	FW	O
DCGPIDCGPâDCGP	DCGPIDCGPâDCGP	NNP	O
=	=	SYM	O
rel1+âi=2prelilog2â¡iPreliminary	rel1+âi=2prelilog2â¡iPreliminary	NNP	O
MD	MD	NNP	O
simulations	simulation	NNS	O
for	for	IN	O
the	the	DT	O
model	model	NN	O
protein	protein	NN	O
was	be	VBD	O
performed	perform	VBN	O
using	use	VBG	O
the	the	DT	O
programme	programme	NN	O
NAMD	NAMD	NNP	O
,	,	,	O
and	and	CC	O
all	all	DT	O
files	file	NNS	O
were	be	VBD	O
generated	generate	VBN	O
using	use	VBG	O
visual	visual	JJ	O
molecular	molecular	JJ	O
dynamics	dynamic	NNS	B
,	,	,	B
.	.	.	O

NAMD	NAMD	NNP	O
is	be	VBZ	O
freely	freely	RB	O
available	available	JJ	O
software	software	NN	O
designed	design	VBN	O
for	for	IN	O
high	high	JJ	O
-	-	HYPH	O
performance	performance	NN	O
simulation	simulation	NN	O
of	of	IN	O
large	large	JJ	O
biomolecular	biomolecular	JJ	O
systems	system	NNS	B
.	.	.	O

During	during	IN	O
MD	MD	NNP	O
simulation	simulation	NN	O
,	,	,	O
the	the	DT	O
minimisation	minimisation	NN	O
and	and	CC	O
equilibration	equilibration	NN	O
of	of	IN	O
the	the	DT	O
original	original	JJ	O
and	and	CC	O
docked	docked	JJ	O
protein	protein	NN	O
were	be	VBD	O
in	in	IN	O
a	a	DT	O
15	15	CD	O
Ã	ã	NN	O
		_SP	O
3	3	CD	O
size	size	NN	O
water	water	NN	O
box	box	NN	O
,	,	,	O
Amber	Amber	NNP	O
10	10	CD	O
EHT	EHT	NNP	O
force	force	NN	O
field	field	NN	O
file	file	NN	O
was	be	VBD	O
applied	apply	VBN	O
for	for	IN	O
energy	energy	NN	O
minimisation	minimisation	NN	O
and	and	CC	O
equilibration	equilibration	NN	O
together	together	RB	O
with	with	IN	O
Gasteiger	Gasteiger	NNP	O
-	-	HYPH	O
Huckel	Huckel	NNP	O
charge	charge	NN	O
using	use	VBG	O
the	the	DT	O
Boltzmann	Boltzmann	NNP	O
initial	initial	JJ	O
velocity	velocity	NN	B
,	,	,	B
.	.	.	O

The	the	DT	O
integrator	integrator	NN	O
parameters	parameter	NNS	O
included	include	VBD	O
2fs	2fs	JJ	O
/	/	SYM	O
step	step	NN	O
for	for	IN	O
all	all	DT	O
rigid	rigid	JJ	O
bonds	bond	NNS	O
and	and	CC	O
nonbonded	nonbonded	JJ	O
frequencies	frequency	NNS	O
were	be	VBD	O
selected	select	VBN	O
for	for	IN	O
1âÃ	1âã	CD	O
		_SP	O
,	,	,	O
and	and	CC	O
full	full	JJ	O
electrostatic	electrostatic	JJ	O
evaluations	evaluation	NNS	O
were	be	VBD	O
conducted	conduct	VBN	O
for	for	IN	O
2âÃ	2âã	CD	O
and	and	CC	O
used	use	VBN	O
with	with	IN	O
ten	ten	CD	O
steps	step	NNS	O
for	for	IN	O
each	each	DT	O
cycle	cycle	NN	B
.	.	.	O

The	the	DT	O
pressure	pressure	NN	O
was	be	VBD	O
maintained	maintain	VBN	O
at	at	IN	O
101.325âkPa	101.325âkpa	CD	O
using	use	VBG	O
the	the	DT	O
Langevin	Langevin	NNP	O
piston	piston	NN	O
and	and	CC	O
temperature	temperature	NN	O
was	be	VBD	O
controlled	control	VBN	O
to	to	IN	O
310âK	310âk	CD	O
using	use	VBG	O
Langevin	Langevin	NNP	O
dynamics	dynamic	NNS	O
.	.	.	O

The	the	DT	O
covalent	covalent	NN	O
interactions	interaction	NNS	O
that	that	WDT	O
exist	exist	VBP	O
between	between	IN	O
hydrogen	hydrogen	NN	O
and	and	CC	O
heavy	heavy	JJ	O
atoms	atom	NNS	O
were	be	VBD	O
observed	observe	VBN	O
to	to	TO	O
be	be	VB	O
in	in	IN	O
constrained	constrain	VBN	O
as	as	IN	O
revealed	reveal	VBN	O
by	by	IN	O
the	the	DT	O
SHAKE	SHAKE	NNP	O
/	/	SYM	O
RATTLE	RATTLE	NNP	O
algorithm	algorithm	NN	B
.	.	.	O

Finally	finally	RB	O
,	,	,	O
a	a	DT	O
10âns	10âns	CD	O
MD	MD	NNP	O
simulation	simulation	NN	O
for	for	IN	O
docked	docked	JJ	O
protein	protein	NN	O
was	be	VBD	O
utilised	utilise	VBN	O
to	to	TO	O
compare	compare	VB	O
and	and	CC	O
verify	verify	VB	O
the	the	DT	O
binding	bind	VBG	O
affinity	affinity	NN	O
and	and	CC	O
stability	stability	NN	O
of	of	IN	O
the	the	DT	O
ligand	ligand	NN	O
-	-	HYPH	O
receptor	receptor	NN	O
complex	complex	NN	O
.	.	.	O

The	the	DT	O
binding	bind	VBG	O
free	free	JJ	O
energies	energy	NNS	O
were	be	VBD	O
estimated	estimate	VBN	O
using	use	VBG	O
the	the	DT	O
molecular	molecular	JJ	O
mechanicsâPoissonâBoltzmann	mechanicsâPoissonâBoltzmann	NNP	O
/	/	SYM	O
surface	surface	NN	O
area	area	NN	O
method	method	NN	O
which	which	WDT	O
is	be	VBZ	O
a	a	DT	O
reliable	reliable	JJ	O
and	and	CC	O
successful	successful	JJ	O
method	method	NN	O
to	to	TO	O
investigate	investigate	VB	O
the	the	DT	O
interaction	interaction	NN	O
between	between	IN	O
the	the	DT	O
ligand	ligand	NN	O
and	and	CC	O
the	the	DT	O
protein	protein	NN	B
,	,	,	B
,	,	,	B
.	.	.	O

The	the	DT	O
300	300	CD	O
snapshots	snapshot	NNS	O
from	from	IN	O
the	the	DT	O
latter	latter	JJ	O
2âns	2âns	CD	O
Molecular	Molecular	NNP	O
Dynamics	Dynamics	NNP	O
trajectories	trajectory	NNS	O
of	of	IN	O
the	the	DT	O
ligand	ligand	NN	O
-	-	HYPH	O
receptor	receptor	NN	O
complexes	complex	NNS	O
were	be	VBD	O
extracted	extract	VBN	O
for	for	IN	O
performing	perform	VBG	O
the	the	DT	O
calculation	calculation	NN	O
of	of	IN	O
the	the	DT	O
binding	bind	VBG	O
free	free	JJ	O
energies	energy	NNS	O
by	by	IN	O
the	the	DT	O
software	software	NN	O
NAMD	NAMD	NNP	O
.	.	.	O

The	the	DT	O
binding	bind	VBG	O
free	free	JJ	O
energies	energy	NNS	O
were	be	VBD	O
calculated	calculate	VBN	O
by	by	IN	O
the	the	DT	O
following	follow	VBG	O
formula	formula	NN	O
:	:	:	O
ÎGbind	îgbind	VB	O
=	=	NFP	O
ÎEvdw+ÎEele+ÎGpolar+ÎGnonpolarThe	ÎEvdw+ÎEele+ÎGpolar+ÎGnonpolarThe	NNP	O
ÎEvdw	îevdw	NN	O
and	and	CC	O
ÎEele	îeele	CD	O
refers	refer	VBZ	O
to	to	IN	O
the	the	DT	O
van	van	NNP	O
der	der	IN	O
Waals	Waals	NNP	O
energy	energy	NN	O
and	and	CC	O
electrostatic	electrostatic	JJ	O
contribution	contribution	NN	O
respectively	respectively	RB	O
,	,	,	O
and	and	CC	O
ÎGpolar	îgpolar	JJ	O
and	and	CC	O
ÎGnonpolar	îgnonpolar	JJ	O
refers	refer	VBZ	O
to	to	IN	O
the	the	DT	O
polar	polar	JJ	O
and	and	CC	O
non	non	JJ	O
-	-	JJ	O
polar	polar	JJ	O
solvation	solvation	NN	O
energy	energy	NN	O
respectively	respectively	RB	O
.	.	.	O

The	the	DT	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
of	of	IN	O
the	the	DT	O
inhibitor	inhibitor	NN	O
on	on	IN	O
kinase	kinase	NNP	O
was	be	VBD	O
measured	measure	VBN	O
using	use	VBG	O
the	the	DT	O
ADP	ADP	NNP	O
-	-	HYPH	O
Glo	Glo	NNP	O
Kinase	Kinase	NNP	O
Assay	Assay	NNP	O
.	.	.	O

The	the	DT	O
ADP	ADP	NNP	O
and	and	CC	O
ATP	ATP	NNP	O
provided	provide	VBN	O
by	by	IN	O
the	the	DT	O
kit	kit	NN	O
were	be	VBD	O
diluted	diluted	JJ	O
to	to	IN	O
40âÂµM	40ââµm	CD	O
with	with	IN	O
a	a	DT	O
kinase	kinase	JJ	O
reaction	reaction	NN	O
buffer	buffer	NN	O
40âmM	40âmm	CD	O
Tris	Tris	NNP	O
,	,	,	O
200âmM	200âmm	CD	O
NaCl	NaCl	NNP	O
,	,	,	O
1âmM	1âmm	CD	O
MgCl2	mgcl2	CD	O
.	.	.	O

The	the	DT	O
test	test	NN	O
compound	compound	NN	O
and	and	CC	O
the	the	DT	O
positive	positive	JJ	O
drug	drug	NN	O
were	be	VBD	O
formulated	formulate	VBN	O
into	into	IN	O
four	four	CD	O
concentration	concentration	NN	O
gradient	gradient	NN	O
solutions	solution	NNS	O
6âÃâ10â2âM	6âãâ10â2âm	CD	O
,	,	,	O
6âÃâ10â4âM	6âãâ10â4âm	CD	O
,	,	,	O
6âÃâ10â6âM	6âãâ10â6âm	CD	O
,	,	,	O
6âÃâ10â8âM	6âãâ10â8âm	CD	O
.	.	.	O

Ten	ten	CD	O
microlitres	microlitre	NNS	O
kinase	kinase	VBD	O
reaction	reaction	NN	O
system	system	NN	O
was	be	VBD	O
shaken	shake	VBN	O
at	at	IN	O
37âÂ	37ââ	CD	O
°	°	,	O
C	C	NNP	O
After	after	IN	O
30âmin	30âmin	NNP	O
,	,	,	O
10âÂµl	10ââµl	CD	O
of	of	IN	O
ADP	ADP	NNP	O
-	-	HYPH	O
Glo	Glo	NNP	O
reagent	reagent	NN	O
was	be	VBD	O
added	add	VBN	O
to	to	TO	O
react	react	VB	O
at	at	IN	O
room	room	NN	O
temperature	temperature	NN	O
for	for	IN	O
40âmin	40âmin	NNP	O
.	.	.	O

Finally	finally	RB	O
,	,	,	O
20âÂµl	20ââµl	CD	O
of	of	IN	O
kinase	kinase	NNP	O
assay	assay	NNP	O
reagent	reagent	NNP	O
was	be	VBD	O
added	add	VBN	O
to	to	TO	O
react	react	VB	O
at	at	IN	O
room	room	NN	O
temperature	temperature	NN	O
for	for	IN	O
30âmin	30âmin	NNP	O
to	to	TO	O
detect	detect	VB	O
chemiluminescence	chemiluminescence	NN	O
values	value	NNS	O
.	.	.	O

The	the	DT	O
HCT116	HCT116	NNP	O
and	and	CC	O
A549	A549	NNP	O
cell	cell	NN	O
lines	line	NNS	O
were	be	VBD	O
cultured	culture	VBN	O
using	use	VBG	O
RPMI1640	RPMI1640	NNP	O
in	in	IN	O
standard	standard	JJ	O
humidified	humidified	JJ	O
incubation	incubation	NN	O
condition	condition	NN	O
at	at	IN	O
37âÂ	37âÂ	NNP	O
°	°	,	O
C	C	NNP	O
in	in	IN	O
5	5	CD	O
%	%	NN	O
CO2	CO2	NNP	O
.	.	.	O

The	the	DT	O
cancer	cancer	NN	O
cells	cell	NNS	O
were	be	VBD	O
placed	place	VBN	O
on	on	IN	O
96-well	96-well	CD	O
plates	plate	NNS	O
in	in	IN	O
triplicate	triplicate	NN	O
.	.	.	O

After	after	IN	O
6âh	6âh	CD	O
,	,	,	O
the	the	DT	O
cells	cell	NNS	O
were	be	VBD	O
treated	treat	VBN	O
with	with	IN	O
a	a	DT	O
series	series	NN	O
of	of	IN	O
concentrations	concentration	NNS	O
of	of	IN	O
Compound	Compound	NNP	O
1	1	CD	O
and	and	CC	O
Compound	Compound	NNP	O
3	3	CD	O
.	.	.	O

The	the	DT	O
positive	positive	JJ	O
control	control	NN	O
contained	contain	VBD	O
the	the	DT	O
same	same	JJ	O
concentrations	concentration	NNS	O
of	of	IN	O
Milciclib	Milciclib	NNP	O
,	,	,	O
and	and	CC	O
the	the	DT	O
negative	negative	JJ	O
control	control	NN	O
received	receive	VBD	O
the	the	DT	O
same	same	JJ	O
volume	volume	NN	O
of	of	IN	O
DMSO	DMSO	NNP	O
.	.	.	O

After	after	IN	O
36âh	36âh	CD	O
incubation	incubation	NN	O
,	,	,	O
cells	cell	NNS	O
were	be	VBD	O
stained	stain	VBN	O
with	with	IN	O
5	5	CD	O
%	%	NN	O
MTT	MTT	NNP	O
10âÂµL	10ââµl	CD	O
/	/	SYM	O
well	well	UH	O
,	,	,	O
and	and	CC	O
the	the	DT	O
optical	optical	JJ	O
density	density	NN	O
was	be	VBD	O
recorded	record	VBN	O
at	at	IN	O
an	an	DT	O
absorbance	absorbance	NN	O
wavelength	wavelength	NN	O
of	of	IN	O
570ânm	570ânm	CD	O
.	.	.	O

The	the	DT	O
constructed	construct	VBN	O
CDK2	CDK2	NNP	O
inhibitor	inhibitor	NN	O
and	and	CC	O
non	non	JJ	O
-	-	JJ	O
inhibitor	inhibitor	JJ	O
training	training	NN	O
set	set	NN	O
contained	contain	VBD	O
298	298	CD	O
inhibitors	inhibitor	NNS	O
and	and	CC	O
10245	10245	CD	O
decoys	decoy	NNS	O
.	.	.	O

Firstly	firstly	RB	O
,	,	,	O
the	the	DT	O
435	435	CD	O
molecular	molecular	JJ	O
descriptors	descriptor	NNS	O
of	of	IN	O
the	the	DT	O
training	training	NN	O
set	set	VBN	O
compounds	compound	NNS	O
were	be	VBD	O
calculated	calculate	VBN	O
by	by	IN	O
the	the	DT	O
Calculate	Calculate	NNP	O
Descriptors	Descriptors	NNPS	O
function	function	VBP	O
in	in	IN	O
MOE2016	MOE2016	NNP	O
software	software	NN	O
,	,	,	O
which	which	WDT	O
included	include	VBD	O
geometrical	geometrical	JJ	O
,	,	,	O
topological	topological	JJ	O
,	,	,	O
and	and	CC	O
electronic	electronic	JJ	O
properties	property	NNS	O
.	.	.	O

Then	then	RB	O
,	,	,	O
the	the	DT	O
435	435	CD	O
descriptors	descriptor	NNS	O
were	be	VBD	O
pre	pre	VBN	O
-	-	VBN	O
processed	process	VBN	O
by	by	IN	O
the	the	DT	O
data	data	NN	O
filter	filter	NN	O
plugin	plugin	NN	O
in	in	IN	O
python	python	NNP	O
to	to	TO	O
remove	remove	VB	O
redundant	redundant	JJ	O
data	datum	NNS	O
:	:	:	O
descriptors	descriptor	NNS	O
with	with	IN	O
large	large	JJ	O
quantities	quantity	NNS	O
of	of	IN	O
null	null	NN	O
,	,	,	O
constant	constant	JJ	O
and	and	CC	O
zero	zero	CD	O
values	value	NNS	O
were	be	VBD	O
eliminated	eliminate	VBN	O
,	,	,	O
descriptors	descriptor	NNS	O
with	with	IN	O
very	very	RB	O
small	small	JJ	O
standard	standard	JJ	O
deviation	deviation	NN	O
values	value	NNS	O
were	be	VBD	O
eliminated	eliminate	VBN	O
,	,	,	O
and	and	CC	O
descriptors	descriptor	NNS	O
with	with	IN	O
high	high	JJ	O
correlation	correlation	NN	O
to	to	IN	O
others	other	NNS	O
were	be	VBD	O
eliminated	eliminate	VBN	O
.	.	.	O

Then	then	RB	O
the	the	DT	O
remained	remain	VBD	O
142	142	CD	O
molecular	molecular	JJ	O
descriptors	descriptor	NNS	O
were	be	VBD	O
normalised	normalise	VBN	O
to	to	IN	O
a	a	DT	O
range	range	NN	O
of	of	IN	O
0	0	CD	O
to	to	IN	O
+1	+1	NNS	O
,	,	,	O
which	which	WDT	O
was	be	VBD	O
necessary	necessary	JJ	O
since	since	IN	O
the	the	DT	O
different	different	JJ	O
ranges	range	NNS	O
of	of	IN	O
descriptor	descriptor	NN	O
values	value	NNS	O
will	will	MD	O
influence	influence	VB	O
the	the	DT	O
quality	quality	NN	O
of	of	IN	O
the	the	DT	O
SVM	SVM	NNP	O
model	model	NN	O
generated	generate	VBN	B
.	.	.	O

Then	then	RB	O
the	the	DT	O
GA	GA	NNP	O
-	-	HYPH	O
SVM	SVM	NNP	O
method	method	NN	O
was	be	VBD	O
utilised	utilise	VBN	O
to	to	TO	O
perform	perform	VB	O
a	a	DT	O
further	further	JJ	O
feature	feature	NN	O
selection	selection	NN	O
process	process	NN	O
to	to	IN	O
these	these	DT	O
142	142	CD	O
normalised	normalise	VBN	O
descriptors	descriptor	NNS	O
.	.	.	O

Finally	finally	RB	O
,	,	,	O
52	52	CD	O
of	of	IN	O
142	142	CD	O
molecular	molecular	JJ	O
descriptors	descriptor	NNS	O
were	be	VBD	O
selected	select	VBN	O
from	from	IN	O
the	the	DT	O
GA	GA	NNP	O
-	-	HYPH	O
SVM	SVM	NNP	O
method	method	NN	O
and	and	CC	O
used	use	VBN	O
for	for	IN	O
further	further	JJ	O
evaluation	evaluation	NN	O
and	and	CC	O
validation	validation	NN	O
,	,	,	O
and	and	CC	O
these	these	DT	O
molecular	molecular	JJ	O
descriptors	descriptor	NNS	O
were	be	VBD	O
divided	divide	VBN	O
into	into	IN	O
10	10	CD	O
groups	group	NNS	O
in	in	IN	O
Table	table	NN	O
1	1	CD	O
.	.	.	O

The	the	DT	O
Grid	Grid	NNP	O
Search	Search	NNP	O
result	result	NN	O
showed	show	VBD	O
that	that	IN	O
the	the	DT	O
parameter	parameter	NN	O
C	C	NNP	O
and	and	CC	O
g	g	NNP	O
with	with	IN	O
the	the	DT	O
value	value	NN	O
of	of	IN	O
32	32	CD	O
and	and	CC	O
0.125	0.125	CD	O
,	,	,	O
the	the	DT	O
LibSVM	LibSVM	NNP	O
model	model	NN	O
demonstrated	demonstrate	VBD	O
the	the	DT	O
best	good	JJS	O
accuracy	accuracy	NN	O
.	.	.	O

The	the	DT	O
52	52	CD	O
molecular	molecular	JJ	O
descriptors	descriptor	NNS	O
filtered	filter	VBN	O
by	by	IN	O
GA	GA	NNP	O
-	-	HYPH	O
SVM	SVM	NNP	O
method	method	NN	O
for	for	IN	O
building	build	VBG	O
SVM	SVM	NNP	O
modelThe	modelThe	NNP	O
ten	ten	CD	O
-	-	HYPH	O
fold	fold	JJ	O
cross	cross	NN	O
-	-	NN	O
validation	validation	NN	O
was	be	VBD	O
utilised	utilise	VBN	O
to	to	TO	O
evaluate	evaluate	VB	O
the	the	DT	O
constructed	construct	VBN	O
SVM	SVM	NNP	O
model	model	NN	O
by	by	IN	O
using	use	VBG	O
the	the	DT	O
training	training	NN	O
set	set	NN	O
.	.	.	O

The	the	DT	O
evaluation	evaluation	NN	O
result	result	NN	O
was	be	VBD	O
showed	show	VBN	O
in	in	IN	O
Table	table	NN	O
2	2	CD	O
,	,	,	O
of	of	IN	O
the	the	DT	O
298	298	CD	O
CDK2	CDK2	NNP	O
inhibitors	inhibitor	NNS	O
,	,	,	O
the	the	DT	O
287	287	CD	O
compounds	compound	NNS	O
were	be	VBD	O
correctly	correctly	RB	O
predicted	predict	VBN	O
and	and	CC	O
11	11	CD	O
compounds	compound	NNS	O
were	be	VBD	O
wrongly	wrongly	RB	O
predicted	predict	VBN	O
,	,	,	O
the	the	DT	O
sensitivity	sensitivity	NN	O
was	be	VBD	O
96.3	96.3	CD	O
%	%	NN	O
.	.	.	O

As	as	IN	O
for	for	IN	O
the	the	DT	O
10245	10245	CD	O
CDK2	CDK2	NNP	O
non	non	NNS	O
-	-	NNS	O
inhibitors	inhibitor	NNS	O
,	,	,	O
10224	10224	CD	O
compounds	compound	NNS	O
were	be	VBD	O
correctly	correctly	RB	O
predicted	predict	VBN	O
and	and	CC	O
21	21	CD	O
compounds	compound	NNS	O
were	be	VBD	O
incorrectly	incorrectly	RB	O
predicted	predict	VBN	O
with	with	IN	O
the	the	DT	O
specificity	specificity	NN	O
value	value	NN	O
of	of	IN	O
99.69	99.69	CD	O
%	%	NN	O
.	.	.	O

The	the	DT	O
overall	overall	JJ	O
accuracy	accuracy	NN	O
was	be	VBD	O
99.79	99.79	CD	O
%	%	NN	O
,	,	,	O
which	which	WDT	O
demonstrated	demonstrate	VBD	O
that	that	IN	O
the	the	DT	O
constructed	construct	VBN	O
SVM	SVM	NNP	O
model	model	NN	O
was	be	VBD	O
appropriate	appropriate	JJ	O
for	for	IN	O
the	the	DT	O
inhibitor	inhibitor	NN	O
and	and	CC	O
non	non	JJ	O
-	-	JJ	O
inhibitor	inhibitor	JJ	O
compounds	compound	NNS	O
in	in	IN	O
training	training	NN	O
dataset	dataset	NN	O
.	.	.	O

Then	then	RB	O
the	the	DT	O
independent	independent	JJ	O
test	test	NN	O
set	set	NN	O
was	be	VBD	O
used	use	VBN	O
to	to	TO	O
validate	validate	VB	O
the	the	DT	O
predictive	predictive	JJ	O
ability	ability	NN	O
of	of	IN	O
the	the	DT	O
constructed	construct	VBN	O
SVM	SVM	NNP	O
model	model	NN	O
to	to	IN	O
the	the	DT	O
dataset	dataset	NN	O
other	other	JJ	O
than	than	IN	O
itself	-PRON-	PRP	O
.	.	.	O

The	the	DT	O
prediction	prediction	NN	O
and	and	CC	O
evaluation	evaluation	NN	O
result	result	NN	O
was	be	VBD	O
showed	show	VBN	O
in	in	IN	O
Table	table	NN	O
2	2	CD	O
.	.	.	O

Of	of	IN	O
the	the	DT	O
70	70	CD	O
CDK2	CDK2	NNP	O
inhibitors	inhibitor	NNS	O
in	in	IN	O
test	test	NN	O
set	set	NN	O
,	,	,	O
there	there	EX	O
were	be	VBD	O
61	61	CD	O
compounds	compound	NNS	O
being	be	VBG	O
correctly	correctly	RB	O
predicted	predict	VBN	O
with	with	IN	O
the	the	DT	O
SE	SE	NNP	O
value	value	NN	O
of	of	IN	O
87.1	87.1	CD	O
%	%	NN	O
.	.	.	O

As	as	IN	O
for	for	IN	O
the	the	DT	O
150	150	CD	O
CDK2	CDK2	NNP	O
non	non	NN	O
-	-	NNS	O
inhibitors	inhibitor	NNS	O
,	,	,	O
there	there	EX	O
were	be	VBD	O
143	143	CD	O
compounds	compound	NNS	O
being	be	VBG	O
correctly	correctly	RB	O
predicted	predict	VBN	O
with	with	IN	O
the	the	DT	O
SP	SP	NNP	O
value	value	NN	O
of	of	IN	O
95.3	95.3	CD	O
%	%	NN	O
.	.	.	O

Of	of	IN	O
all	all	PDT	O
the	the	DT	O
220	220	CD	O
compounds	compound	NNS	O
in	in	IN	O
the	the	DT	O
test	test	NN	O
set	set	NN	O
,	,	,	O
there	there	EX	O
were	be	VBD	O
204	204	CD	O
compounds	compound	NNS	O
being	be	VBG	O
correctly	correctly	RB	O
predicted	predict	VBN	O
with	with	IN	O
the	the	DT	O
Q	Q	NNP	O
value	value	NN	O
of	of	IN	O
92.72	92.72	CD	O
%	%	NN	O
.	.	.	O

Validation	validation	NN	O
and	and	CC	O
evaluation	evaluation	NN	O
results	result	NNS	O
of	of	IN	O
the	the	DT	O
ten	ten	CD	O
-	-	HYPH	O
fold	fold	JJ	O
cross	cross	NN	O
-	-	NN	O
validation	validation	JJ	O
and	and	CC	O
independent	independent	JJ	O
test	test	NN	O
indicated	indicate	VBD	O
that	that	IN	O
the	the	DT	O
constructed	construct	VBN	O
SVM	SVM	NNP	O
model	model	NN	O
fit	fit	JJ	O
with	with	IN	O
both	both	CC	O
training	training	NN	O
set	set	NN	O
and	and	CC	O
test	test	NN	O
set	set	NN	O
,	,	,	O
possessed	possess	VBD	O
high	high	JJ	O
accuracy	accuracy	NN	O
and	and	CC	O
predictive	predictive	JJ	O
ability	ability	NN	O
.	.	.	O

The	the	DT	O
evaluation	evaluation	NN	O
and	and	CC	O
validation	validation	NN	O
result	result	NN	O
of	of	IN	O
the	the	DT	O
ten	ten	CD	O
-	-	HYPH	O
fold	fold	JJ	O
cross	cross	NN	O
-	-	NN	O
validation	validation	JJ	O
and	and	CC	O
independent	independent	JJ	O
test	test	NN	O
.	.	.	O

The	the	DT	O
66	66	CD	O
CDK2	CDK2	NNP	O
crystal	crystal	NN	O
structures	structure	NNS	O
with	with	IN	O
the	the	DT	O
inhibitor	inhibitor	NN	O
were	be	VBD	O
collected	collect	VBN	O
from	from	IN	O
PDB	PDB	NNP	O
database	database	NN	O
.	.	.	O

All	all	PDT	O
the	the	DT	O
superposed	superpose	VBN	O
ligand	ligand	NN	O
-	-	HYPH	O
receptor	receptor	NN	O
complexes	complex	NNS	O
were	be	VBD	O
imported	import	VBN	O
into	into	IN	O
the	the	DT	O
MOE	MOE	NNP	O
database	database	NN	O
for	for	IN	O
calculating	calculate	VBG	O
the	the	DT	O
PLIF	PLIF	NNP	O
rows	row	NNS	O
,	,	,	O
and	and	CC	O
then	then	RB	O
these	these	DT	O
PLIF	PLIF	NNP	O
rows	row	NNS	O
were	be	VBD	O
utilised	utilise	VBN	O
for	for	IN	O
generating	generate	VBG	O
the	the	DT	O
amino	amino	JJ	O
acids	acid	NNS	O
interaction	interaction	NN	O
fingerprints	fingerprint	NNS	O
.	.	.	O

As	as	IN	O
depicted	depict	VBN	O
in	in	IN	O
Figure	Figure	NNP	O
2	2	CD	O
,	,	,	O
the	the	DT	O
single	single	JJ	O
letter	letter	NN	O
codes	code	NNS	O
of	of	IN	O
the	the	DT	O
residues	residue	NNS	O
for	for	IN	O
which	which	WDT	O
fingerprint	fingerprint	NN	O
bits	bit	NNS	O
were	be	VBD	O
generated	generate	VBN	O
.	.	.	O

The	the	DT	O
66	66	CD	O
CDK2	CDK2	NNP	O
inhibitors	inhibitor	NNS	O
formed	form	VBN	O
with	with	IN	O
interaction	interaction	NN	O
with	with	IN	O
residues	residue	NNS	O
Ile10	Ile10	NNP	O
,	,	,	O
Gly13	Gly13	NNP	O
,	,	,	O
Val18	Val18	NNP	O
,	,	,	O
Lys33	Lys33	NNP	O
,	,	,	O
Glu81	Glu81	NNP	O
,	,	,	O
Phe82	Phe82	NNP	O
,	,	,	O
Leu83	Leu83	NNP	O
,	,	,	O
Gln85	Gln85	NNP	O
,	,	,	O
Asp86	Asp86	NNP	O
,	,	,	O
Lys89	Lys89	NNP	O
,	,	,	O
Gln131	gln131	CD	O
and	and	CC	O
Asp145	asp145	CD	O
.	.	.	O

The	the	DT	O
residues	residue	NNS	O
Leu83	Leu83	NNP	O
had	have	VBD	O
the	the	DT	O
most	most	RBS	O
single	single	JJ	O
letter	letter	NN	O
codes	code	NNS	O
,	,	,	O
which	which	WDT	O
demonstrated	demonstrate	VBD	O
that	that	IN	O
almost	almost	RB	O
all	all	PDT	O
the	the	DT	O
CDK2	CDK2	NNP	O
inhibitors	inhibitor	NNS	O
generate	generate	VBP	O
interaction	interaction	NN	O
with	with	IN	O
the	the	DT	O
Leu83	Leu83	NNP	O
.	.	.	O

The	the	DT	O
moiety	moiety	NN	O
of	of	IN	O
residues	residue	NNS	O
Glu81	Glu81	NNP	O
,	,	,	O
Lys33	Lys33	NNP	O
and	and	CC	O
Asp86	Asp86	NNP	O
also	also	RB	O
formed	form	VBD	O
many	many	JJ	O
interactions	interaction	NNS	O
with	with	IN	O
the	the	DT	O
inhibitor	inhibitor	NN	O
in	in	IN	O
the	the	DT	O
ATP	ATP	NNP	O
-	-	HYPH	O
competitive	competitive	JJ	O
pocket	pocket	NN	O
.	.	.	O

Most	Most	JJS	O
compounds	compound	NNS	O
exhibited	exhibit	VBD	O
the	the	DT	O
hydrogen	hydrogen	NN	O
bond	bond	NN	O
interaction	interaction	NN	O
with	with	IN	O
Leu83	Leu83	NNP	O
and	and	CC	O
Glu81	Glu81	NNP	O
,	,	,	O
and	and	CC	O
the	the	DT	O
residues	residue	NNS	O
Asp83	Asp83	NNP	O
formed	form	VBD	O
the	the	DT	O
highest	high	JJS	O
number	number	NN	O
of	of	IN	O
interaction	interaction	NN	O
types	type	NNS	O
which	which	WDT	O
included	include	VBD	O
side	side	NN	O
-	-	HYPH	O
chain	chain	NN	O
hydrogen	hydrogen	NN	O
bond	bond	NN	O
donor	donor	NN	O
,	,	,	O
backbone	backbone	NN	O
hydrogen	hydrogen	NN	O
bond	bond	NN	O
acceptor	acceptor	NN	O
,	,	,	O
ionic	ionic	JJ	O
attraction	attraction	NN	O
and	and	CC	O
surface	surface	NN	O
contact	contact	NN	O
.	.	.	O

Based	base	VBN	O
on	on	IN	O
these	these	DT	O
interaction	interaction	NN	O
fingerprints	fingerprint	NNS	O
,	,	,	O
four	four	CD	O
pharmacophore	pharmacophore	NN	O
models	model	NNS	O
were	be	VBD	O
elicited	elicit	VBN	O
and	and	CC	O
further	further	RB	O
evaluated	evaluate	VBD	O
their	-PRON-	PRP$	O
performance	performance	NN	O
by	by	IN	O
the	the	DT	O
CDK2	CDK2	NNP	O
inhibitor	inhibitor	NN	O
and	and	CC	O
non	non	JJ	O
-	-	JJ	O
inhibitor	inhibitor	JJ	O
training	training	NN	O
set	set	VBN	O
to	to	TO	O
select	select	VB	O
the	the	DT	O
best	good	JJS	O
one	one	CD	O
.	.	.	O

The	the	DT	O
result	result	NN	O
of	of	IN	O
the	the	DT	O
evaluation	evaluation	NN	O
was	be	VBD	O
showed	show	VBN	O
in	in	IN	O
Table	table	NN	O
3	3	CD	O
,	,	,	O
the	the	DT	O
pharmacophore	pharmacophore	NN	O
model	model	NN	O
3	3	CD	O
with	with	IN	O
the	the	DT	O
highest	high	JJS	O
values	value	NNS	O
of	of	IN	O
yields	yield	NNS	O
showed	show	VBD	O
that	that	IN	O
the	the	DT	O
267	267	CD	O
of	of	IN	O
the	the	DT	O
298	298	CD	O
CDK2	CDK2	NNP	O
inhibitors	inhibitor	NNS	O
were	be	VBD	O
correctly	correctly	RB	O
predicted	predict	VBN	O
and	and	CC	O
2127	2127	CD	O
of	of	IN	O
10245	10245	CD	O
CDK2	CDK2	NNP	O
non	non	NNS	O
-	-	NNS	O
inhibitors	inhibitor	NNS	O
were	be	VBD	O
also	also	RB	O
matched	match	VBN	O
properly	properly	RB	O
with	with	IN	O
this	this	DT	O
pharmacophore	pharmacophore	NN	O
model	model	NN	O
.	.	.	O

All	all	PDT	O
the	the	DT	O
pharmacophore	pharmacophore	NN	O
models	model	NNS	O
had	have	VBD	O
the	the	DT	O
ability	ability	NN	O
to	to	TO	O
differentiate	differentiate	VB	O
the	the	DT	O
CDK2	CDK2	NNP	O
inhibitors	inhibitor	NNS	O
from	from	IN	O
non	non	JJ	O
-	-	NNS	O
inhibitors	inhibitor	NNS	O
to	to	IN	O
some	some	DT	O
degree	degree	NN	O
.	.	.	O

But	but	CC	O
these	these	DT	O
models	model	NNS	O
also	also	RB	O
bring	bring	VBP	O
a	a	DT	O
large	large	JJ	O
number	number	NN	O
of	of	IN	O
false	false	JJ	O
positive	positive	JJ	O
prediction	prediction	NN	O
results	result	NNS	O
,	,	,	O
that	that	RB	O
is	be	VBZ	O
the	the	DT	O
reason	reason	NN	O
we	-PRON-	PRP	O
adopted	adopt	VBD	O
the	the	DT	O
multistage	multistage	NN	O
virtual	virtual	JJ	O
screening	screening	NN	O
method	method	NN	O
.	.	.	O

The	the	DT	O
barcodes	barcode	NNS	O
and	and	CC	O
letter	letter	NN	O
mode	mode	NN	O
of	of	IN	O
the	the	DT	O
amino	amino	NNP	O
acids	acids	NNP	O
interaction	interaction	NNP	O
fingerprint	fingerprint	NN	O
generated	generate	VBN	O
by	by	IN	O
MOE2016	MOE2016	NNP	O
software	software	NN	O
.	.	.	O

The	the	DT	O
best	good	JJS	O
pharmacophore	pharmacophore	NN	O
models	model	NNS	O
evaluated	evaluate	VBN	O
by	by	IN	O
training	train	VBG	O
set	set	NN	O
,	,	,	O
the	the	DT	O
purple	purple	JJ	O
and	and	CC	O
cyan	cyan	NNP	O
features	feature	NNS	O
indicted	indict	VBD	O
the	the	DT	O
hydrogen	hydrogen	NN	O
-	-	HYPH	O
bond	bond	NN	O
donor	donor	NN	O
and	and	CC	O
acceptor	acceptor	NN	O
respectively	respectively	RB	O
.	.	.	O

The	the	DT	O
matching	matching	NN	O
of	of	IN	O
the	the	DT	O
pharmacophore	pharmacophore	NN	O
with	with	IN	O
the	the	DT	O
superposed	superpose	VBN	O
structures	structure	NNS	O
indicates	indicate	VBZ	O
that	that	IN	O
the	the	DT	O
pharmacophore	pharmacophore	NN	O
can	can	MD	O
describe	describe	VB	O
the	the	DT	O
superposition	superposition	NN	O
characteristics	characteristic	NNS	O
of	of	IN	O
the	the	DT	O
substituent	substituent	NN	O
of	of	IN	O
the	the	DT	O
66	66	CD	O
CDK2	CDK2	NNP	O
inhibitors	inhibitor	NNS	O
well	well	RB	O
.	.	.	O

The	the	DT	O
evaluation	evaluation	NN	O
and	and	CC	O
validation	validation	NN	O
result	result	NN	O
of	of	IN	O
the	the	DT	O
four	four	CD	O
Pharmacophore	Pharmacophore	NNP	O
models	model	NNS	O
generated	generate	VBN	O
by	by	IN	O
PLIF	PLIF	NNP	O
.	.	.	O

The	the	DT	O
optimisation	optimisation	NN	O
of	of	IN	O
docking	dock	VBG	O
parameter	parameter	NN	O
and	and	CC	O
selection	selection	NN	O
of	of	IN	O
the	the	DT	O
function	function	NN	O
score	score	NN	O
are	be	VBP	O
considered	consider	VBN	O
important	important	JJ	O
in	in	IN	O
the	the	DT	O
process	process	NN	O
of	of	IN	O
docking	dock	VBG	O
virtual	virtual	JJ	O
screening	screening	NN	O
because	because	IN	O
it	-PRON-	PRP	O
has	have	VBZ	O
a	a	DT	O
great	great	JJ	O
impact	impact	NN	O
on	on	IN	O
the	the	DT	O
final	final	JJ	O
results	result	NNS	O
.	.	.	O

The	the	DT	O
crystal	crystal	NN	O
structure	structure	NN	O
of	of	IN	O
the	the	DT	O
kinase	kinase	NN	O
domain	domain	NN	O
of	of	IN	O
CDK2	CDK2	NNP	O
complexes	complex	NNS	O
with	with	IN	O
4-amino	4-amino	CD	O
-	-	HYPH	O
N--2-[amino]-1,3-thiazole-5-carboxamide	N--2-[amino]-1,3-thiazole-5-carboxamide	NNP	O
RC-2â142	RC-2â142	NNP	O
was	be	VBD	O
chosen	choose	VBN	O
as	as	IN	O
the	the	DT	O
reference	reference	NN	O
structure	structure	NN	O
of	of	IN	O
the	the	DT	O
receptor	receptor	NN	O
since	since	IN	O
it	-PRON-	PRP	O
has	have	VBZ	O
the	the	DT	O
highest	high	JJS	O
resolution	resolution	NN	O
2.1âÃ	2.1âã	CD	O
		_SP	O
among	among	IN	O
all	all	PDT	O
the	the	DT	O
CDK2	CDK2	NNP	O
crystal	crystal	NN	O
structures	structure	NNS	B
,	,	,	B
.	.	.	O

In	in	IN	O
order	order	NN	O
to	to	TO	O
determine	determine	VB	O
the	the	DT	O
best	good	JJS	O
docking	docking	NN	O
parameters	parameter	NNS	O
,	,	,	O
eight	eight	CD	O
active	active	JJ	O
compounds	compound	NNS	O
that	that	WDT	O
have	have	VBP	O
been	be	VBN	O
co	co	VBN	O
-	-	VBN	O
crystallized	crystallized	JJ	O
with	with	IN	O
CDK2	CDK2	NNP	O
were	be	VBD	O
docked	dock	VBN	O
back	back	RB	O
to	to	IN	O
the	the	DT	O
active	active	JJ	O
site	site	NN	O
of	of	IN	O
CDK2	CDK2	NNP	B
.	.	.	O

The	the	DT	O
parameters	parameter	NNS	O
in	in	IN	O
GOLD	gold	JJ	O
panel	panel	NN	O
in	in	IN	O
MOE2016	MOE2016	NNP	O
software	software	NN	O
were	be	VBD	O
reconfigured	reconfigure	VBN	O
to	to	TO	O
be	be	VB	O
as	as	RB	O
similar	similar	JJ	O
as	as	IN	O
possible	possible	JJ	O
to	to	IN	O
the	the	DT	O
original	original	JJ	O
build	build	NN	O
-	-	HYPH	O
in	in	RP	O
inhibitor	inhibitor	NN	O
structures	structure	NNS	O
in	in	IN	O
the	the	DT	O
ATP	ATP	NNP	O
-	-	HYPH	O
competitive	competitive	JJ	O
pocket	pocket	NN	O
binding	binding	NN	O
site	site	NN	O
of	of	IN	O
CDK2	CDK2	NNP	O
.	.	.	O

The	the	DT	O
calculated	calculated	JJ	O
values	value	NNS	O
of	of	IN	O
root	root	NN	O
mean	mean	VBP	O
square	square	JJ	O
deviation	deviation	NN	O
between	between	IN	O
the	the	DT	O
docked	docked	JJ	O
active	active	JJ	O
compounds	compound	NNS	O
and	and	CC	O
the	the	DT	O
crystallized	crystallized	JJ	O
structures	structure	NNS	O
in	in	IN	O
CDK2	CDK2	NNP	O
were	be	VBD	O
showed	show	VBN	O
in	in	IN	O
Table	table	NN	O
4	4	CD	O
.	.	.	O

All	all	PDT	O
the	the	DT	O
RMSD	rmsd	JJ	O
values	value	NNS	O
were	be	VBD	O
less	less	JJR	O
than	than	IN	O
2.1âÃ	2.1âã	CD	O
		_SP	O
,	,	,	O
which	which	WDT	O
manifested	manifest	VBD	O
that	that	IN	O
the	the	DT	O
GOLD	gold	NN	O
plugin	plugin	NN	O
in	in	IN	O
MOE2016	MOE2016	NNP	O
software	software	NN	O
have	have	VBP	O
the	the	DT	O
capability	capability	NN	O
of	of	IN	O
getting	get	VBG	O
the	the	DT	O
credible	credible	JJ	O
ligand	ligand	NN	O
-	-	HYPH	O
receptor	receptor	NN	O
CDK2	CDK2	NNP	O
complexes	complex	NNS	O
in	in	IN	O
this	this	DT	O
series	series	NN	O
of	of	IN	O
configuration	configuration	NN	O
.	.	.	O

The	the	DT	O
RMSD	rmsd	JJ	O
values	value	NNS	O
of	of	IN	O
the	the	DT	O
eight	eight	CD	O
active	active	JJ	O
compounds	compound	NNS	O
between	between	IN	O
their	-PRON-	PRP$	O
docking	docking	NN	O
conformation	conformation	NN	O
result	result	NN	O
and	and	CC	O
build	build	NN	O
-	-	HYPH	O
in	in	RP	O
ligand	ligand	NN	O
in	in	IN	O
CDK2	CDK2	NNP	O
inhibitors	inhibitor	NNS	O
.	.	.	O

In	in	IN	O
the	the	DT	O
case	case	NN	O
of	of	IN	O
selecting	select	VBG	O
the	the	DT	O
function	function	NN	O
score	score	NN	O
,	,	,	O
the	the	DT	O
50	50	CD	O
CDK2	CDK2	NNP	O
inhibitors	inhibitor	NNS	O
with	with	IN	O
defined	define	VBN	O
IC50	IC50	NNP	O
values	value	NNS	O
were	be	VBD	O
docked	dock	VBN	O
into	into	IN	O
the	the	DT	O
active	active	JJ	O
pocket	pocket	NN	O
of	of	IN	O
the	the	DT	O
CDK2	CDK2	NNP	O
inhibitors	inhibitor	NNS	O
.	.	.	O

The	the	DT	O
results	result	NNS	O
of	of	IN	O
NDCG	NDCG	NNP	O
were	be	VBD	O
showed	show	VBN	O
in	in	IN	O
Table	Table	NNP	O
S3	S3	NNP	O
:	:	:	O
Four	four	CD	O
function	function	NN	O
score	score	NN	O
GoldScore	GoldScore	NNP	O
,	,	,	O
ChemScore	ChemScore	NNP	O
,	,	,	O
ASP	ASP	NNP	O
and	and	CC	O
PLP	PLP	NNP	O
values	value	NNS	O
of	of	IN	O
the	the	DT	O
50	50	CD	O
inhibitors	inhibitor	NNS	O
were	be	VBD	O
calculated	calculate	VBN	O
respectively	respectively	RB	O
for	for	IN	O
comparing	compare	VBG	O
the	the	DT	O
order	order	NN	O
to	to	IN	O
the	the	DT	O
values	value	NNS	O
of	of	IN	O
IC50	IC50	NNP	O
.	.	.	O

The	the	DT	O
Values	value	NNS	O
of	of	IN	O
ChemScore	ChemScore	NNP	O
demonstrated	demonstrate	VBD	O
the	the	DT	O
highest	high	JJS	O
consistency	consistency	NN	O
to	to	IN	O
the	the	DT	O
experimental	experimental	JJ	O
IC50	IC50	NNP	O
.	.	.	O

Finally	finally	RB	O
,	,	,	O
the	the	DT	O
ChemScore	ChemScore	NNP	O
function	function	NN	O
score	score	NN	O
was	be	VBD	O
utilised	utilise	VBN	O
to	to	TO	O
evaluate	evaluate	VB	O
the	the	DT	O
results	result	NNS	O
of	of	IN	O
the	the	DT	O
Docking	Docking	NNP	O
-	-	HYPH	O
Virtual	virtual	JJ	O
Screening	screening	NN	O
.	.	.	O

The	the	DT	O
training	training	NN	O
set	set	NN	O
was	be	VBD	O
utilised	utilise	VBN	O
to	to	TO	O
evaluate	evaluate	VB	O
and	and	CC	O
validate	validate	VB	O
the	the	DT	O
GOLD	gold	NN	O
docking	docking	NN	O
with	with	IN	O
setting	set	VBG	O
parameters	parameter	NNS	O
.	.	.	O

With	with	IN	O
the	the	DT	O
threshold	threshold	NN	O
function	function	NN	O
value	value	NN	O
of	of	IN	O
7.0	7.0	CD	O
,	,	,	O
the	the	DT	O
246	246	CD	O
of	of	IN	O
298	298	CD	O
CDK2	CDK2	NNP	O
inhibitors	inhibitor	NNS	O
were	be	VBD	O
correctly	correctly	RB	O
predicted	predict	VBN	O
with	with	IN	O
the	the	DT	O
yield	yield	NN	O
of	of	IN	O
82.5	82.5	CD	O
%	%	NN	O
,	,	,	O
and	and	CC	O
1120	1120	CD	O
of	of	IN	O
10245	10245	CD	O
decoys	decoy	NNS	O
were	be	VBD	O
also	also	RB	O
wrongly	wrongly	RB	O
predicted	predict	VBN	O
as	as	IN	O
the	the	DT	O
CDK2	CDK2	NNP	O
inhibitors	inhibitor	NNS	O
.	.	.	O

Similar	similar	JJ	O
to	to	IN	O
the	the	DT	O
pharmacophore	pharmacophore	NN	O
model	model	NN	O
virtual	virtual	JJ	O
screening	screening	NN	O
,	,	,	O
the	the	DT	O
docking	docking	NN	O
process	process	NN	O
also	also	RB	O
had	have	VBD	O
the	the	DT	O
ability	ability	NN	O
to	to	TO	O
distinguish	distinguish	VB	O
the	the	DT	O
CDK2	CDK2	NNP	O
inhibitors	inhibitor	NNS	O
from	from	IN	O
the	the	DT	O
training	training	NN	O
set	set	NN	O
,	,	,	O
but	but	CC	O
the	the	DT	O
multistage	multistage	NN	O
virtual	virtual	JJ	O
screening	screening	NN	O
method	method	NN	O
made	make	VBD	O
sense	sense	NN	O
because	because	IN	O
of	of	IN	O
the	the	DT	O
high	high	JJ	O
TP	TP	NNP	O
suffered	suffer	VBD	O
in	in	IN	O
the	the	DT	O
result	result	NN	O
of	of	IN	O
docking	dock	VBG	O
virtual	virtual	JJ	O
screening	screening	NN	O
.	.	.	O

Each	each	DT	O
of	of	IN	O
the	the	DT	O
virtual	virtual	JJ	O
screening	screening	NN	O
methods	method	NNS	O
has	have	VBZ	O
its	-PRON-	PRP$	O
advantages	advantage	NNS	O
and	and	CC	O
disadvantages	disadvantage	NNS	O
in	in	IN	O
terms	term	NNS	O
of	of	IN	O
speed	speed	NN	O
and	and	CC	O
prediction	prediction	NN	O
accuracy	accuracy	NN	O
,	,	,	O
and	and	CC	O
all	all	DT	O
of	of	IN	O
them	-PRON-	PRP	O
suffer	suffer	VBP	O
from	from	IN	O
a	a	DT	O
high	high	JJ	O
false	false	JJ	O
-	-	HYPH	O
positive	positive	JJ	O
rate	rate	NN	O
.	.	.	O

Multilevel	multilevel	JJ	O
virtual	virtual	JJ	O
filtering	filtering	NN	O
is	be	VBZ	O
composed	compose	VBN	O
of	of	IN	O
SVM	SVM	NNP	O
,	,	,	O
pharmacophore	pharmacophore	NN	O
and	and	CC	O
docking	dock	VBG	O
virtual	virtual	JJ	O
screening	screening	NN	O
method	method	NN	O
.	.	.	O

The	the	DT	O
three	three	CD	O
filters	filter	NNS	O
were	be	VBD	O
cascaded	cascade	VBN	O
by	by	IN	O
using	use	VBG	O
the	the	DT	O
fastest	fast	JJS	O
SVM	SVM	NNP	O
filters	filter	NNS	O
first	first	RB	O
,	,	,	O
then	then	RB	O
medium	medium	JJ	O
speed	speed	NN	O
filters	filter	NNS	O
,	,	,	O
and	and	CC	O
the	the	DT	O
slowest	slow	JJS	O
docking	docking	NN	O
filters	filter	NNS	O
at	at	IN	O
the	the	DT	O
end	end	NN	O
.	.	.	O

The	the	DT	O
validation	validation	NN	O
set	set	NN	O
will	will	MD	O
be	be	VB	O
utilised	utilise	VBN	O
for	for	IN	O
evaluating	evaluate	VBG	O
and	and	CC	O
validating	validate	VBG	O
the	the	DT	O
performance	performance	NN	O
of	of	IN	O
this	this	DT	O
multistage	multistage	NN	O
virtual	virtual	JJ	O
screening	screening	NN	O
method	method	NN	O
.	.	.	O

During	during	IN	O
the	the	DT	O
process	process	NN	O
of	of	IN	O
validating	validate	VBG	O
and	and	CC	O
evaluating	evaluate	VBG	O
the	the	DT	O
multistage	multistage	NN	O
virtual	virtual	JJ	O
screening	screening	NN	O
method	method	NN	O
,	,	,	O
the	the	DT	O
SVM	SVM	NNP	O
,	,	,	O
pharmacophore	pharmacophore	NN	O
and	and	CC	O
docking	dock	VBG	O
virtual	virtual	JJ	O
screening	screening	NN	O
method	method	NN	O
were	be	VBD	O
individually	individually	RB	O
performed	perform	VBN	O
for	for	IN	O
screening	screen	VBG	O
the	the	DT	O
CDK2	CDK2	NNP	O
inhibitors	inhibitor	NNS	O
from	from	IN	O
the	the	DT	O
validation	validation	NN	O
set	set	VBN	O
first	first	RB	O
.	.	.	O

To	to	TO	O
evaluate	evaluate	VB	O
the	the	DT	O
prediction	prediction	NN	O
accuracy	accuracy	NN	O
of	of	IN	O
virtual	virtual	JJ	O
screening	screening	NN	O
,	,	,	O
the	the	DT	O
yield	yield	NN	O
,	,	,	O
hit	hit	VBD	O
rate	rate	NN	O
,	,	,	O
and	and	CC	O
enrichment	enrichment	NN	O
factor	factor	NN	O
were	be	VBD	O
assessed	assess	VBN	O
in	in	IN	O
Table	table	NN	O
5	5	CD	O
.	.	.	O

For	for	IN	O
the	the	DT	O
SVM	SVM	NNP	O
model	model	NN	O
,	,	,	O
313	313	CD	O
of	of	IN	O
375	375	CD	O
CDK2	CDK2	NNP	O
inhibitors	inhibitor	NNS	O
were	be	VBD	O
correctly	correctly	RB	O
predicted	predict	VBN	O
and	and	CC	O
the	the	DT	O
number	number	NN	O
of	of	IN	O
negatives	negative	NNS	O
was	be	VBD	O
153253	153253	CD	O
,	,	,	O
the	the	DT	O
values	value	NNS	O
of	of	IN	O
yield	yield	NN	O
,	,	,	O
hit	hit	VBD	O
rate	rate	NN	O
and	and	CC	O
enrichment	enrichment	NN	O
factor	factor	NN	O
were	be	VBD	O
83.5	83.5	CD	O
%	%	NN	O
,	,	,	O
12.1	12.1	CD	O
%	%	NN	O
and	and	CC	O
50.3	50.3	CD	O
%	%	NN	O
respectively	respectively	RB	O
.	.	.	O

The	the	DT	O
time	time	NN	O
spent	spend	VBN	O
in	in	IN	O
the	the	DT	O
process	process	NN	O
of	of	IN	O
screening	screen	VBG	O
the	the	DT	O
validation	validation	NN	O
set	set	VBN	O
by	by	IN	O
SVM	SVM	NNP	O
model	model	NN	O
was	be	VBD	O
0.2âh	0.2âh	ADD	O
on	on	IN	O
the	the	DT	O
desktop	desktop	NN	O
computer	computer	NN	O
with	with	IN	O
8	8	CD	O
processors	processor	NNS	O
of	of	IN	O
IntelR	IntelR	NNP	O
XeonR	XeonR	NNP	O
CPU	CPU	NNP	O
E5	E5	NNP	O
-	-	HYPH	O
1620@	1620@	CD	O
3.70âGHz	3.70âghz	CD	O
.	.	.	O

For	for	IN	O
the	the	DT	O
pharmacophore	pharmacophore	NN	O
virtual	virtual	JJ	O
screening	screening	NN	O
method	method	NN	O
,	,	,	O
the	the	DT	O
number	number	NN	O
of	of	IN	O
predicted	predict	VBN	O
positive	positive	JJ	O
was	be	VBD	O
28108	28108	CD	O
.	.	.	O

313	313	CD	O
of	of	IN	O
them	-PRON-	PRP	O
were	be	VBD	O
correctly	correctly	RB	O
predicted	predict	VBN	O
with	with	IN	O
a	a	DT	O
yield	yield	NN	O
of	of	IN	O
87.2	87.2	CD	O
%	%	NN	O
,	,	,	O
the	the	DT	O
values	value	NNS	O
of	of	IN	O
hit	hit	VBN	O
rate	rate	NN	O
and	and	CC	O
enrichment	enrichment	NN	O
factor	factor	NN	O
were	be	VBD	O
1.17	1.17	CD	O
%	%	NN	O
and	and	CC	O
4.86	4.86	CD	O
respectively	respectively	RB	O
.	.	.	O

The	the	DT	O
time	time	NN	O
used	use	VBN	O
in	in	IN	O
the	the	DT	O
pharmacophore	pharmacophore	NN	O
virtual	virtual	JJ	O
screening	screening	NN	O
was	be	VBD	O
6.95âh	6.95âh	CD	O
.	.	.	O

For	for	IN	O
docking	dock	VBG	O
virtual	virtual	JJ	O
screening	screening	NN	O
,	,	,	O
the	the	DT	O
290	290	CD	O
of	of	IN	O
375	375	CD	O
CDK2	CDK2	NNP	O
inhibitors	inhibitor	NNS	O
were	be	VBD	O
correctly	correctly	RB	O
predicted	predict	VBN	O
and	and	CC	O
other	other	JJ	O
17211	17211	CD	O
decoys	decoy	NNS	O
were	be	VBD	O
also	also	RB	O
wrongly	wrongly	RB	O
predicted	predict	VBN	O
as	as	IN	O
the	the	DT	O
positive	positive	JJ	O
inhibitors	inhibitor	NNS	O
.	.	.	O

The	the	DT	O
result	result	NN	O
of	of	IN	O
the	the	DT	O
hit	hit	NN	O
rate	rate	NN	O
,	,	,	O
the	the	DT	O
enrichment	enrichment	NN	O
factor	factor	NN	O
and	and	CC	O
the	the	DT	O
value	value	NN	O
of	of	IN	O
yield	yield	NN	O
was	be	VBD	O
1.66	1.66	CD	O
%	%	NN	O
,	,	,	O
6.90	6.90	CD	O
and	and	CC	O
77.3	77.3	CD	O
,	,	,	O
the	the	DT	O
time	time	NN	O
cost	cost	NN	O
in	in	IN	O
this	this	DT	O
process	process	NN	O
was	be	VBD	O
378.28âh	378.28âh	CD	O
.	.	.	O

Hence	hence	RB	O
,	,	,	O
the	the	DT	O
SVM	SVM	NNP	O
method	method	NN	O
was	be	VBD	O
selected	select	VBN	O
as	as	IN	O
the	the	DT	O
first	first	JJ	O
filter	filter	NN	O
,	,	,	O
the	the	DT	O
pharmacophore	pharmacophore	NN	O
and	and	CC	O
docking	docking	NN	O
method	method	NN	O
were	be	VBD	O
selected	select	VBN	O
as	as	IN	O
the	the	DT	O
second	second	JJ	O
and	and	CC	O
third	third	JJ	O
one	one	NN	O
respectively	respectively	RB	O
.	.	.	O

Validation	validation	NN	O
and	and	CC	O
evaluation	evaluation	VB	O
the	the	DT	O
various	various	JJ	O
virtual	virtual	JJ	O
screening	screening	NN	O
method	method	NN	O
by	by	IN	O
the	the	DT	O
validation	validation	NN	O
set	set	VBD	O
that	that	WDT	O
contains	contain	VBZ	O
375	375	CD	O
known	know	VBN	O
CDK2	CDK2	NNP	O
inhibitors	inhibitor	NNS	O
and	and	CC	O
155528	155528	CD	O
decoys	decoy	NNS	O
.	.	.	O

Then	then	RB	O
,	,	,	O
SVM	SVM	NNP	O
method	method	NN	O
was	be	VBD	O
combined	combine	VBN	O
with	with	IN	O
pharmacophore	pharmacophore	NN	O
method	method	NN	O
to	to	TO	O
investigate	investigate	VB	O
the	the	DT	O
speed	speed	NN	O
and	and	CC	O
accuracy	accuracy	NN	O
of	of	IN	O
screening	screen	VBG	O
validation	validation	NN	O
set	set	VBN	O
.	.	.	O

After	after	IN	O
SVM	SVM	NNP	O
virtual	virtual	JJ	O
screening	screening	NN	O
method	method	NN	O
,	,	,	O
313	313	CD	O
of	of	IN	O
375	375	CD	O
CDK2	CDK2	NNP	O
inhibitors	inhibitor	NNS	O
were	be	VBD	O
correctly	correctly	RB	O
predicted	predict	VBN	O
and	and	CC	O
153253	153253	CD	O
of	of	IN	O
155520	155520	CD	O
decoys	decoy	NNS	O
were	be	VBD	O
correctly	correctly	RB	O
predicted	predict	VBN	O
,	,	,	O
so	so	RB	O
the	the	DT	O
set	set	NN	O
compose	compose	JJR	O
of	of	IN	O
2275	2275	CD	O
decoys	decoy	NNS	O
and	and	CC	O
313	313	CD	O
CDK2	CDK2	NNP	O
inhibitors	inhibitor	NNS	O
were	be	VBD	O
selected	select	VBN	O
as	as	IN	O
the	the	DT	O
initial	initial	JJ	O
set	set	NN	O
for	for	IN	O
combined	combine	VBN	O
virtual	virtual	JJ	O
screening	screening	NN	O
method	method	NN	O
.	.	.	O

For	for	IN	O
the	the	DT	O
SVM	SVM	NNP	O
-	-	HYPH	O
pharmacophore	pharmacophore	NN	O
virtual	virtual	JJ	O
screening	screening	NN	O
method	method	NN	O
,	,	,	O
298	298	CD	O
of	of	IN	O
313	313	CD	O
CDK2	CDK2	NNP	O
inhibitors	inhibitor	NNS	O
were	be	VBD	O
correctly	correctly	RB	O
predicted	predict	VBN	O
with	with	IN	O
a	a	DT	O
yield	yield	NN	O
of	of	IN	O
79.4	79.4	CD	O
%	%	NN	O
.	.	.	O

The	the	DT	O
value	value	NN	O
of	of	IN	O
hit	hit	VBN	O
rate	rate	NN	O
and	and	CC	O
enrichment	enrichment	NN	O
factor	factor	NN	O
were	be	VBD	O
28.5	28.5	CD	O
%	%	NN	O
and	and	CC	O
118.32	118.32	CD	O
respectively	respectively	RB	O
,	,	,	O
the	the	DT	O
time	time	NN	O
cost	cost	NN	O
in	in	IN	O
this	this	DT	O
combined	combine	VBN	O
method	method	NN	O
was	be	VBD	O
0.93âh	0.93âh	,	O
.	.	.	O

The	the	DT	O
combination	combination	NN	O
of	of	IN	O
the	the	DT	O
two	two	CD	O
methods	method	NNS	O
was	be	VBD	O
better	well	JJR	O
than	than	IN	O
either	either	DT	O
SVM	SVM	NNP	O
method	method	NN	O
or	or	CC	O
pharmacophore	pharmacophore	NN	O
method	method	NN	O
alone	alone	RB	O
in	in	IN	O
terms	term	NNS	O
of	of	IN	O
both	both	DT	O
speed	speed	NN	O
and	and	CC	O
accuracy	accuracy	NN	O
.	.	.	O

This	this	DT	O
is	be	VBZ	O
because	because	IN	O
the	the	DT	O
false	false	JJ	O
positive	positive	JJ	O
of	of	IN	O
SVM	SVM	NNP	O
method	method	NN	O
in	in	IN	O
the	the	DT	O
screening	screening	NN	O
process	process	NN	O
is	be	VBZ	O
far	far	RB	O
less	less	JJR	O
than	than	IN	O
that	that	DT	O
of	of	IN	O
pharmacophore	pharmacophore	NN	O
method	method	NN	O
and	and	CC	O
method	method	NN	O
3	3	CD	O
.	.	.	O

The	the	DT	O
introduction	introduction	NN	O
of	of	IN	O
SVM	SVM	NNP	O
method	method	NN	O
as	as	IN	O
the	the	DT	O
first	first	JJ	O
level	level	NN	O
filter	filter	NN	O
will	will	MD	O
increase	increase	VB	O
the	the	DT	O
proportion	proportion	NN	O
of	of	IN	O
correct	correct	JJ	O
positive	positive	JJ	O
results	result	NNS	O
in	in	IN	O
all	all	DT	O
predicted	predict	VBN	O
positive	positive	JJ	O
results	result	NNS	O
.	.	.	O

Therefore	therefore	RB	O
,	,	,	O
the	the	DT	O
values	value	NNS	O
of	of	IN	O
hit	hit	VBN	O
-	-	HYPH	O
rate	rate	NN	O
and	and	CC	O
enrichment	enrichment	NN	O
factor	factor	NN	O
will	will	MD	O
be	be	VB	O
increased	increase	VBN	O
greatly	greatly	RB	O
to	to	TO	O
facilitate	facilitate	VB	O
distinguishing	distinguish	VBG	O
the	the	DT	O
positive	positive	JJ	O
and	and	CC	O
negative	negative	JJ	O
element	element	NN	O
.	.	.	O

Finally	finally	RB	O
,	,	,	O
the	the	DT	O
multistage	multistage	NN	O
virtual	virtual	JJ	O
screening	screening	NN	O
method	method	NN	O
based	base	VBN	O
on	on	IN	O
SVM	SVM	NNP	O
,	,	,	O
pharmacophore	pharmacophore	NN	O
and	and	CC	O
docking	docking	NN	O
model	model	NN	O
was	be	VBD	O
performed	perform	VBN	O
to	to	TO	O
screen	screen	VB	O
the	the	DT	O
CDK2	CDK2	NNP	O
inhibitors	inhibitor	NNS	O
in	in	IN	O
validation	validation	NN	O
set	set	VBN	O
.	.	.	O

The	the	DT	O
combined	combined	JJ	O
method	method	NN	O
got	get	VBD	O
a	a	DT	O
set	set	NN	O
of	of	IN	O
749	749	CD	O
CDK2	CDK2	NNP	O
non	non	NNS	O
-	-	NNS	O
inhibitors	inhibitor	NNS	O
and	and	CC	O
298	298	CD	O
inhibitors	inhibitor	NNS	O
,	,	,	O
after	after	IN	O
performing	perform	VBG	O
the	the	DT	O
docking	dock	VBG	O
virtual	virtual	JJ	O
screening	screening	NN	O
method	method	NN	O
,	,	,	O
the	the	DT	O
277	277	CD	O
CDK2	CDK2	NNP	O
inhibitors	inhibitor	NNS	O
and	and	CC	O
680	680	CD	O
non	non	NNS	O
-	-	NNS	O
inhibitors	inhibitor	NNS	O
were	be	VBD	O
correctly	correctly	RB	O
predicted	predict	VBN	O
.	.	.	O

The	the	DT	O
value	value	NN	O
of	of	IN	O
yield	yield	NN	O
,	,	,	O
hit	hit	VBN	O
-	-	HYPH	O
rate	rate	NN	O
,	,	,	O
and	and	CC	O
enrichment	enrichment	NN	O
factor	factor	NN	O
were	be	VBD	O
73.8	73.8	CD	O
%	%	NN	O
,	,	,	O
80.1	80.1	CD	O
%	%	NN	O
and	and	CC	O
332.83	332.83	CD	O
respectively	respectively	RB	O
,	,	,	O
the	the	DT	O
whole	whole	JJ	O
multistage	multistage	NN	O
virtual	virtual	JJ	O
screening	screening	NN	O
process	process	NN	O
took	take	VBD	O
1.62âh	1.62âh	CD	O
.	.	.	O

The	the	DT	O
multistage	multistage	NN	O
virtual	virtual	JJ	O
screening	screening	NN	O
method	method	NN	O
got	get	VBD	O
the	the	DT	O
highest	high	JJS	O
hit	hit	VBN	O
-	-	HYPH	O
rate	rate	NN	O
among	among	IN	O
other	other	JJ	O
methods	method	NNS	O
which	which	WDT	O
was	be	VBD	O
up	up	IN	O
to	to	IN	O
80.1	80.1	CD	O
%	%	NN	O
.	.	.	O

With	with	IN	O
the	the	DT	O
addition	addition	NN	O
of	of	IN	O
docking	docking	NN	O
method	method	NN	O
,	,	,	O
the	the	DT	O
accuracy	accuracy	NN	O
of	of	IN	O
virtual	virtual	JJ	O
screening	screening	NN	O
has	have	VBZ	O
been	be	VBN	O
greatly	greatly	RB	O
improved	improve	VBN	O
than	than	IN	O
the	the	DT	O
combined	combined	JJ	O
method	method	NN	O
,	,	,	O
although	although	IN	O
it	-PRON-	PRP	O
came	come	VBD	O
with	with	IN	O
a	a	DT	O
slight	slight	JJ	O
loss	loss	NN	O
of	of	IN	O
the	the	DT	O
yield	yield	NN	O
.	.	.	O

Moreover	moreover	RB	O
,	,	,	O
the	the	DT	O
screening	screening	NN	O
time	time	NN	O
of	of	IN	O
the	the	DT	O
slower	slow	JJR	O
pharmacophore	pharmacophore	NN	O
and	and	CC	O
docking	docking	NN	O
method	method	NN	O
was	be	VBD	O
significantly	significantly	RB	O
reduced	reduce	VBN	O
because	because	IN	O
the	the	DT	O
fastest	fast	JJS	O
SVM	SVM	NNP	O
method	method	NN	O
ignored	ignore	VBD	O
too	too	RB	O
many	many	JJ	O
negative	negative	JJ	O
results	result	NNS	O
initially	initially	RB	O
.	.	.	O

We	-PRON-	PRP	O
found	find	VBD	O
that	that	IN	O
all	all	PDT	O
the	the	DT	O
separate	separate	JJ	O
virtual	virtual	JJ	O
screening	screening	NN	O
methods	method	NNS	O
were	be	VBD	O
not	not	RB	O
as	as	RB	O
efficient	efficient	JJ	O
and	and	CC	O
accurate	accurate	JJ	O
as	as	IN	O
the	the	DT	O
multistage	multistage	NN	O
method	method	NN	O
as	as	IN	O
the	the	DT	O
following	follow	VBG	O
aspects	aspect	NNS	O
:	:	:	O
all	all	PDT	O
the	the	DT	O
separate	separate	JJ	O
approach	approach	NN	O
virtual	virtual	JJ	O
screening	screening	NN	O
method	method	NN	O
suffer	suffer	VBP	O
from	from	IN	O
the	the	DT	O
problem	problem	NN	O
that	that	WDT	O
positive	positive	JJ	O
results	result	NNS	O
accounted	account	VBD	O
for	for	IN	O
a	a	DT	O
high	high	JJ	O
proportion	proportion	NN	O
of	of	IN	O
predicted	predict	VBN	O
positive	positive	JJ	O
results	result	NNS	O
.	.	.	O

This	this	DT	O
will	will	MD	O
result	result	VB	O
in	in	IN	O
a	a	DT	O
low	low	JJ	O
hit	hit	VBN	O
-	-	HYPH	O
rate	rate	NN	O
and	and	CC	O
enrichment	enrichment	NN	O
factor	factor	NN	O
particularly	particularly	RB	O
in	in	IN	O
pharmacophore	pharmacophore	NN	O
and	and	CC	O
docking	docking	NN	O
method	method	NN	O
,	,	,	O
the	the	DT	O
hit	hit	VBN	O
-	-	HYPH	O
rate	rate	NN	O
and	and	CC	O
enrichment	enrichment	NN	O
factor	factor	NN	O
are	be	VBP	O
less	less	JJR	O
than	than	IN	O
2	2	CD	O
%	%	NN	O
and	and	CC	O
which	which	WDT	O
is	be	VBZ	O
untrustworthy	untrustworthy	JJ	O
and	and	CC	O
meaningless	meaningless	JJ	O
in	in	IN	O
virtual	virtual	JJ	O
screening	screening	NN	O
result	result	NN	O
;	;	:	O
in	in	IN	O
the	the	DT	O
case	case	NN	O
of	of	IN	O
screening	screen	VBG	O
the	the	DT	O
large	large	JJ	O
chemical	chemical	JJ	O
library	library	NN	O
containing	contain	VBG	O
millions	million	NNS	O
or	or	CC	O
even	even	RB	O
tens	ten	NNS	O
of	of	IN	O
millions	million	NNS	O
of	of	IN	O
compounds	compound	NNS	O
by	by	IN	O
performed	perform	VBD	O
the	the	DT	O
pharmacophore	pharmacophore	NN	O
and	and	CC	O
docking	docking	NN	O
method	method	NN	O
,	,	,	O
in	in	IN	O
addition	addition	NN	O
to	to	IN	O
the	the	DT	O
problem	problem	NN	O
of	of	IN	O
time	time	NN	O
-	-	HYPH	O
consuming	consume	VBG	O
process	process	NN	O
,	,	,	O
we	-PRON-	PRP	O
should	should	MD	O
also	also	RB	O
consider	consider	VB	O
that	that	IN	O
the	the	DT	O
ligand	ligand	NN	O
-	-	HYPH	O
based	base	VBN	O
and	and	CC	O
structure	structure	NN	O
-	-	HYPH	O
based	base	VBN	O
method	method	NN	O
are	be	VBP	O
often	often	RB	O
hard	hard	JJ	O
to	to	TO	O
find	find	VB	O
compounds	compound	NNS	O
with	with	IN	O
novel	novel	JJ	O
scaffolds	scaffold	NNS	O
.	.	.	O

And	and	CC	O
using	use	VBG	O
SVM	SVM	NNP	O
method	method	NN	O
alone	alone	RB	O
will	will	MD	O
result	result	VB	O
in	in	IN	O
over	over	RB	O
-	-	HYPH	O
fitting	fitting	NN	O
between	between	IN	O
the	the	DT	O
constructed	construct	VBN	O
SVM	SVM	NNP	O
model	model	NN	O
and	and	CC	O
the	the	DT	O
training	training	NN	O
set	set	NN	O
which	which	WDT	O
can	can	MD	O
not	not	RB	O
be	be	VB	O
verified	verify	VBN	O
and	and	CC	O
avoided	avoid	VBN	O
by	by	IN	O
subsequent	subsequent	JJ	O
methods	method	NNS	O
.	.	.	O

The	the	DT	O
multistage	multistage	NN	O
virtual	virtual	JJ	O
screening	screening	NN	O
method	method	NN	O
was	be	VBD	O
utilised	utilise	VBN	O
to	to	TO	O
screen	screen	VB	O
the	the	DT	O
CDK2	CDK2	NNP	O
inhibitors	inhibitor	NNS	O
from	from	IN	O
the	the	DT	O
chemical	chemical	NNP	O
database	database	NN	O
NCI	NCI	NNP	O
,	,	,	O
Enamine	Enamine	NNP	O
and	and	CC	O
Pubchem	Pubchem	NNP	O
.	.	.	O

The	the	DT	O
30120	30120	CD	O
positive	positive	JJ	O
compounds	compound	NNS	O
obtained	obtain	VBN	O
from	from	IN	O
the	the	DT	O
first	first	JJ	O
SVM	SVM	NNP	O
virtual	virtual	JJ	O
screening	screening	NN	O
approach	approach	NN	O
.	.	.	O

These	these	DT	O
compounds	compound	NNS	O
continued	continue	VBD	O
to	to	TO	O
be	be	VB	O
filtered	filter	VBN	O
using	use	VBG	O
pharmacophore	pharmacophore	NN	O
method	method	NN	O
,	,	,	O
and	and	CC	O
then	then	RB	O
5541	5541	CD	O
positive	positive	JJ	O
compounds	compound	NNS	O
were	be	VBD	O
screened	screen	VBN	O
.	.	.	O

After	after	IN	O
implementing	implement	VBG	O
the	the	DT	O
final	final	JJ	O
GOLD	gold	JJ	O
docking	docking	NN	O
approach	approach	NN	O
,	,	,	O
we	-PRON-	PRP	O
ended	end	VBD	O
up	up	RP	O
with	with	IN	O
310	310	CD	O
compounds	compound	NNS	O
in	in	IN	O
Table	Table	NNP	O
S4	s4	NN	O
.	.	.	O

Moreover	moreover	RB	O
,	,	,	O
the	the	DT	O
fingerprint	fingerprint	NN	O
BIT	BIT	NNP	O
-	-	HYPH	O
MACCS	MACCS	NNP	O
of	of	IN	O
all	all	DT	O
compounds	compound	NNS	O
was	be	VBD	O
calculated	calculate	VBN	O
by	by	IN	O
MOE2016	MOE2016	NNP	O
software	software	NN	O
,	,	,	O
the	the	DT	O
310	310	CD	O
compounds	compound	NNS	O
were	be	VBD	O
divided	divide	VBN	O
into	into	IN	O
10	10	CD	O
groups	group	NNS	O
according	accord	VBG	O
to	to	IN	O
the	the	DT	O
similarity	similarity	NN	O
metric	metric	NN	O
of	of	IN	O
tanimoto	tanimoto	NNP	O
coefficient	coefficient	NN	O
.	.	.	O

One	one	CD	O
representative	representative	JJ	O
compound	compound	NN	O
was	be	VBD	O
selected	select	VBN	O
in	in	IN	O
each	each	DT	O
group	group	NN	O
based	base	VBN	O
on	on	IN	O
the	the	DT	O
number	number	NN	O
of	of	IN	O
interactions	interaction	NNS	O
with	with	IN	O
important	important	JJ	O
amino	amino	JJ	O
acids	acid	NNS	O
and	and	CC	O
the	the	DT	O
degree	degree	NN	O
of	of	IN	O
difficulty	difficulty	NN	O
in	in	IN	O
synthesis	synthesis	NN	O
.	.	.	O

Finally	finally	RB	O
,	,	,	O
six	six	CD	O
compounds	compound	NNS	O
with	with	IN	O
novel	novel	JJ	O
scaffolds	scaffold	NNS	O
were	be	VBD	O
selected	select	VBN	O
for	for	IN	O
the	the	DT	O
further	further	JJ	O
molecular	molecular	JJ	O
dynamics	dynamic	NNS	O
experiments	experiment	NNS	O
.	.	.	O

We	-PRON-	PRP	O
further	further	RB	O
analysed	analyse	VBD	O
the	the	DT	O
drug	drug	NN	O
-	-	HYPH	O
like	like	JJ	O
properties	property	NNS	O
of	of	IN	O
the	the	DT	O
best	good	JJS	O
hits	hit	NNS	O
and	and	CC	O
we	-PRON-	PRP	O
observed	observe	VBD	O
that	that	IN	O
all	all	DT	O
of	of	IN	O
them	-PRON-	PRP	O
satisfied	satisfy	VBD	O
the	the	DT	O
Lipinski	Lipinski	NNP	O
's	's	POS	O
rule	rule	NN	O
of	of	IN	O
five	five	CD	O
.	.	.	O

The	the	DT	O
six	six	CD	O
compounds	compound	NNS	O
with	with	IN	O
novel	novel	JJ	O
scaffolds	scaffold	NNS	O
obtained	obtain	VBN	O
from	from	IN	O
the	the	DT	O
multistage	multistage	NN	O
virtual	virtual	JJ	O
screening	screening	NN	O
method	method	NN	O
.	.	.	O

The	the	DT	O
molecular	molecular	JJ	O
dynamics	dynamic	NNS	O
results	result	NNS	O
of	of	IN	O
the	the	DT	O
Milciclib	Milciclib	NNP	O
and	and	CC	O
the	the	DT	O
six	six	CD	O
hit	hit	NN	O
compounds	compound	NNS	O
were	be	VBD	O
showed	show	VBN	O
in	in	IN	O
Figure	Figure	NNP	O
4(AâF	4(aâf	CD	O
.	.	.	O

The	the	DT	O
RMSD	rmsd	JJ	O
plot	plot	NN	O
of	of	IN	O
the	the	DT	O
Milciclib	Milciclib	NNP	O
-	-	HYPH	O
CDK2	CDK2	NNP	O
complex	complex	NN	O
exhibited	exhibit	VBD	O
a	a	DT	O
sharp	sharp	JJ	O
upward	upward	JJ	O
trend	trend	NN	O
in	in	IN	O
the	the	DT	O
first	first	JJ	O
3âns	3âns	CD	O
,	,	,	O
then	then	RB	O
the	the	DT	O
value	value	NN	O
of	of	IN	O
the	the	DT	O
RMSD	RMSD	NNP	O
plot	plot	NN	O
was	be	VBD	O
flat	flat	JJ	O
around	around	RB	O
2âÃ	2âã	CD	O
until	until	IN	O
the	the	DT	O
end	end	NN	O
of	of	IN	O
the	the	DT	O
simulation	simulation	NN	O
.	.	.	O

Out	out	IN	O
of	of	IN	O
all	all	DT	O
six	six	CD	O
compound	compound	NN	O
-	-	HYPH	O
CDK2	cdk2	NN	O
complexes	complex	NNS	O
,	,	,	O
only	only	RB	O
the	the	DT	O
Compound	Compound	NNP	O
1	1	CD	O
and	and	CC	O
Compounds	Compounds	NNPS	O
3	3	CD	O
showed	show	VBD	O
the	the	DT	O
same	same	JJ	O
stability	stability	NN	O
to	to	IN	O
CDK2	CDK2	NNP	O
receptor	receptor	NN	O
as	as	IN	O
Milciclib	Milciclib	NNP	O
.	.	.	O

In	in	IN	O
Figure	figure	NN	O
4	4	CD	O
,	,	,	O
the	the	DT	O
RMSD	rmsd	JJ	O
plot	plot	NN	O
of	of	IN	O
Compound	Compound	NNP	O
1-CDK2	1-CDK2	NNS	O
reached	reach	VBD	O
to	to	IN	O
2âÃ	2âã	CD	O
in	in	IN	O
2.8âns	2.8ân	NNS	O
and	and	CC	O
it	-PRON-	PRP	O
kept	keep	VBD	O
a	a	DT	O
little	little	JJ	O
fluctuating	fluctuate	VBG	O
around	around	IN	O
that	that	DT	O
value	value	NN	O
until	until	IN	O
the	the	DT	O
end	end	NN	O
of	of	IN	O
10âns	10âns	CD	O
.	.	.	O

In	in	IN	O
Figure	figure	NN	O
4	4	CD	O
,	,	,	O
the	the	DT	O
RMSD	RMSD	NNP	O
plot	plot	NN	O
of	of	IN	O
compound	compound	NN	O
3-CDK2	3-cdk2	CD	O
showed	show	VBD	O
the	the	DT	O
same	same	JJ	O
tendency	tendency	NN	O
to	to	IN	O
Milciclib	Milciclib	NNP	O
-	-	HYPH	O
CDK2	CDK2	NNP	O
plot	plot	NN	O
in	in	IN	O
the	the	DT	O
first	first	JJ	O
7âns	7âns	CD	O
.	.	.	O

Although	although	IN	O
the	the	DT	O
values	value	NNS	O
had	have	VBD	O
a	a	DT	O
small	small	JJ	O
fluctuation	fluctuation	NN	O
around	around	IN	O
2	2	CD	O
to	to	IN	O
2.5âÃ	2.5âã	CD	O
		_SP	O
,	,	,	O
it	-PRON-	PRP	O
was	be	VBD	O
still	still	RB	O
levelled	level	VBN	O
off	off	RP	O
around	around	IN	O
2âÃ	2âã	CD	O
at	at	IN	O
the	the	DT	O
end	end	NN	O
of	of	IN	O
simulation	simulation	NN	O
.	.	.	O

The	the	DT	O
other	other	JJ	O
four	four	CD	O
compounds	compound	NNS	O
either	either	CC	O
had	have	VBD	O
problems	problem	NNS	O
of	of	IN	O
serious	serious	JJ	O
fluctuation	fluctuation	NN	O
in	in	IN	O
CDK2	CDK2	NNP	O
pocket	pocket	NN	O
Compound	Compound	NNP	O
2-CDK2	2-cdk2	CD	O
and	and	CC	O
Compound	Compound	NNP	O
5-CDK2	5-cdk2	CD	O
in	in	IN	O
Figure	Figure	NNP	O
4respectively	4respectively	CD	O
or	or	CC	O
demonstrated	demonstrate	VBD	O
higher	high	JJR	O
RMSD	rmsd	JJ	O
values	value	NNS	O
than	than	IN	O
Milciclib	Milciclib	NNP	O
-	-	HYPH	O
CDK2	CDK2	NNP	O
complex	complex	NN	O
Compound	Compound	NNP	O
4-CDK2	4-CDK2	NNS	O
and	and	CC	O
Compound	Compound	NNP	O
6-CDK2	6-cdk2	CD	O
in	in	IN	O
Figure	Figure	NNP	O
4respectively	4respectively	CD	O
,	,	,	O
so	so	CC	O
it	-PRON-	PRP	O
's	be	VBZ	O
unstable	unstable	JJ	O
when	when	WRB	O
it	-PRON-	PRP	O
bound	bind	VBD	O
to	to	IN	O
the	the	DT	O
ATP	ATP	NNP	O
competitive	competitive	JJ	O
pocket	pocket	NN	O
of	of	IN	O
CDK2	CDK2	NNP	O
.	.	.	O

The	the	DT	O
molecular	molecular	JJ	O
dynamics	dynamic	NNS	O
results	result	NNS	O
of	of	IN	O
the	the	DT	O
Milciclib	Milciclib	NNP	O
and	and	CC	O
six	six	CD	O
screened	screened	JJ	O
compounds	compound	NNS	O
,	,	,	O
the	the	DT	O
RMSD	RMSD	NNP	O
of	of	IN	O
Milciclib	Milciclib	NNP	O
-	-	HYPH	O
CDK2	CDK2	NNP	O
complex	complex	NN	O
was	be	VBD	O
painted	paint	VBN	O
in	in	IN	O
red	red	NNP	O
,	,	,	O
the	the	DT	O
six	six	CD	O
screened	screened	JJ	O
compounds	compound	NNS	O
were	be	VBD	O
painted	paint	VBN	O
in	in	IN	O
blue	blue	JJ	O
in	in	IN	O
AâF	AâF	NNP	O
.	.	.	O

The	the	DT	O
result	result	NN	O
of	of	IN	O
the	the	DT	O
Binding	bind	VBG	O
free	free	JJ	O
energy	energy	NN	O
calculation	calculation	NN	O
was	be	VBD	O
depicted	depict	VBN	O
in	in	IN	O
Table	Table	NNP	O
6	6	CD	O
.	.	.	O

The	the	DT	O
van	van	NNP	O
der	der	NN	O
Waals	Waals	NNP	O
energy	energy	NN	O
,	,	,	O
electrostatic	electrostatic	JJ	O
contribution	contribution	NN	O
and	and	CC	O
nonpolar	nonpolar	JJ	O
energy	energy	NN	O
were	be	VBD	O
favourable	favourable	JJ	O
for	for	IN	O
the	the	DT	O
stability	stability	NN	O
of	of	IN	O
the	the	DT	O
binding	bind	VBG	O
pattern	pattern	NN	O
,	,	,	O
while	while	IN	O
the	the	DT	O
polar	polar	JJ	O
energy	energy	NN	O
was	be	VBD	O
unfavourable	unfavourable	JJ	O
.	.	.	O

There	there	EX	O
was	be	VBD	O
no	no	DT	O
significant	significant	JJ	O
difference	difference	NN	O
in	in	IN	O
the	the	DT	O
polar	polar	JJ	O
energy	energy	NN	O
and	and	CC	O
nonpolar	nonpolar	JJ	O
energy	energy	NN	O
values	value	NNS	O
of	of	IN	O
the	the	DT	O
six	six	CD	O
compounds	compound	NNS	O
,	,	,	O
so	so	CC	O
the	the	DT	O
main	main	JJ	O
effect	effect	NN	O
of	of	IN	O
the	the	DT	O
binding	bind	VBG	O
free	free	JJ	O
energy	energy	NN	O
were	be	VBD	O
the	the	DT	O
van	van	NNP	O
der	der	IN	O
Waals	Waals	NNP	O
energy	energy	NN	O
and	and	CC	O
electrostatic	electrostatic	JJ	O
contribution	contribution	NN	O
.	.	.	O

The	the	DT	O
Compound	Compound	NNP	O
1	1	CD	O
and	and	CC	O
Compound	Compound	NNP	O
3	3	CD	O
with	with	IN	O
the	the	DT	O
binding	bind	VBG	O
free	free	JJ	O
energy	energy	NN	O
values	value	NNS	O
of	of	IN	O
â258.98âKJ	â258.98âKJ	NNP	O
/	/	SYM	O
mol	mol	NNP	O
and	and	CC	O
â252.94âKJ	â252.94âKJ	NNP	O
/	/	SYM	O
mol	mol	NNP	O
respectively	respectively	RB	O
exhibited	exhibit	VBD	O
the	the	DT	O
similar	similar	JJ	O
values	value	NNS	O
of	of	IN	O
binding	bind	VBG	O
free	free	JJ	O
energy	energy	NN	O
to	to	IN	O
Milciclib	Milciclib	NNP	O
â260.30âKJ	â260.30âKJ	NNP	O
/	/	SYM	O
mol	mol	NN	O
.	.	.	O

The	the	DT	O
other	other	JJ	O
four	four	CD	O
screened	screened	JJ	O
compounds	compound	NNS	O
possessed	possess	VBD	O
higher	higher	RBR	O
binding	bind	VBG	O
free	free	JJ	O
energy	energy	NN	O
than	than	IN	O
Milciclib	Milciclib	NNP	O
,	,	,	O
indicated	indicate	VBD	O
that	that	IN	O
these	these	DT	O
four	four	CD	O
compounds	compound	NNS	O
were	be	VBD	O
not	not	RB	O
sufficiently	sufficiently	RB	O
stable	stable	JJ	O
to	to	IN	O
the	the	DT	O
active	active	JJ	O
pocket	pocket	NN	O
of	of	IN	O
CDK2	CDK2	NNP	O
.	.	.	O

The	the	DT	O
compound	compound	NN	O
2	2	CD	O
,	,	,	O
4	4	CD	O
,	,	,	O
5	5	CD	O
and	and	CC	O
6	6	CD	O
exhibited	exhibit	VBD	O
the	the	DT	O
relatively	relatively	RB	O
high	high	JJ	O
van	van	NNP	O
der	der	IN	O
Waals	Waals	NNP	O
energy	energy	NN	O
,	,	,	O
electrostatic	electrostatic	JJ	O
contribution	contribution	NN	O
.	.	.	O

The	the	DT	O
higher	high	JJR	O
van	van	NNP	O
der	der	NN	O
Waals	Waals	NNP	O
energy	energy	NN	O
and	and	CC	O
electrostatic	electrostatic	JJ	O
contribution	contribution	NN	O
value	value	NN	O
were	be	VBD	O
,	,	,	O
the	the	DT	O
more	more	RBR	O
likely	likely	JJ	O
it	-PRON-	PRP	O
is	be	VBZ	O
that	that	IN	O
the	the	DT	O
compound	compound	NN	O
will	will	MD	O
be	be	VB	O
solvated	solvate	VBN	O
and	and	CC	O
will	will	MD	O
not	not	RB	O
interact	interact	VB	O
with	with	IN	O
the	the	DT	O
residues	residue	NNS	O
in	in	IN	O
the	the	DT	O
active	active	JJ	O
site	site	NN	O
of	of	IN	O
the	the	DT	O
CDK2	CDK2	NNP	O
.	.	.	O

Binding	bind	VBG	O
free	free	JJ	O
energy	energy	NN	O
of	of	IN	O
the	the	DT	O
Milciclib	Milciclib	NNP	O
and	and	CC	O
six	six	CD	O
potential	potential	JJ	O
CDK2	CDK2	NNP	O
inhibitors	inhibitor	NNS	O
.	.	.	O

The	the	DT	O
result	result	NN	O
of	of	IN	O
the	the	DT	O
binding	bind	VBG	O
free	free	JJ	O
energy	energy	NN	O
calculation	calculation	NN	O
demonstrated	demonstrate	VBD	O
that	that	IN	O
the	the	DT	O
compound	compound	NN	O
1	1	CD	O
and	and	CC	O
compound	compound	NNP	O
3	3	CD	O
have	have	VB	O
the	the	DT	O
potent	potent	JJ	O
binding	binding	JJ	O
stability	stability	NN	O
to	to	IN	O
CDK2	CDK2	NNP	O
.	.	.	O

The	the	DT	O
binding	bind	VBG	O
mode	mode	NN	O
of	of	IN	O
Compound	Compound	NNP	O
1	1	CD	O
and	and	CC	O
Compound	Compound	NNP	O
3	3	CD	O
at	at	IN	O
different	different	JJ	O
simulation	simulation	NN	O
stages	stage	NNS	O
0âns	0âns	NFP	O
and	and	CC	O
10âns	10âns	CD	O
were	be	VBD	O
showed	show	VBN	O
in	in	IN	O
Figure	Figure	NNP	O
5(AâD	5(aâd	CD	O
.	.	.	O

Compound	Compound	NNP	O
1	1	CD	O
formed	form	VBD	O
the	the	DT	O
hydrogen	hydrogen	NN	O
bonds	bond	NNS	O
with	with	IN	O
Val18	Val18	NNP	O
and	and	CC	O
Thr14	Thr14	NNP	O
at	at	IN	O
0âns	0âns	CD	O
when	when	WRB	O
interacting	interact	VBG	O
with	with	IN	O
CDK2	CDK2	NNP	O
.	.	.	O

When	when	WRB	O
the	the	DT	O
simulation	simulation	NN	O
was	be	VBD	O
over	over	RB	O
and	and	CC	O
the	the	DT	O
complex	complex	NN	O
was	be	VBD	O
stable	stable	JJ	O
,	,	,	O
the	the	DT	O
interaction	interaction	NN	O
of	of	IN	O
Thr14	Thr14	NNP	O
was	be	VBD	O
lost	lose	VBN	O
but	but	CC	O
two	two	CD	O
new	new	JJ	O
interactions	interaction	NNS	O
were	be	VBD	O
generated	generate	VBN	O
.	.	.	O

The	the	DT	O
benzdioxan	benzdioxan	VBN	O
moiety	moiety	NN	O
formed	form	VBD	O
the	the	DT	O
aromatic	aromatic	JJ	O
ring	ring	NN	O
interaction	interaction	NN	O
to	to	IN	O
the	the	DT	O
residue	residue	JJ	O
Val18	Val18	NNP	O
,	,	,	O
and	and	CC	O
the	the	DT	O
aromatic	aromatic	JJ	O
ring	ring	NN	O
interaction	interaction	NN	O
and	and	CC	O
thioether	thioether	NN	O
chains	chain	NNS	O
also	also	RB	O
generated	generate	VBD	O
the	the	DT	O
hydrogen	hydrogen	NN	O
bonds	bond	NNS	O
interaction	interaction	NN	O
to	to	IN	O
the	the	DT	O
residues	residue	NNS	O
Glu81	Glu81	NNP	O
,	,	,	O
His84	His84	NNP	O
and	and	CC	O
Leu83	Leu83	NNP	O
.	.	.	O

Almost	almost	RB	O
all	all	DT	O
of	of	IN	O
these	these	DT	O
effects	effect	NNS	O
occur	occur	VBP	O
when	when	WRB	O
an	an	DT	O
inhibitor	inhibitor	NN	O
binds	bind	NNS	O
to	to	IN	O
CDK2	CDK2	NNP	O
Figure	Figure	NNP	O
2	2	CD	O
.	.	.	O

Two	two	CD	O
hydrogen	hydrogen	NN	O
bonds	bond	NNS	O
were	be	VBD	O
generated	generate	VBN	O
by	by	IN	O
interacting	interact	VBG	O
with	with	IN	O
Glu81	Glu81	NNP	O
and	and	CC	O
Leu83	Leu83	NNP	O
residues	residue	NNS	O
in	in	IN	O
the	the	DT	O
0âns	0âns	CD	O
of	of	IN	O
compound	compound	NN	O
3	3	CD	O
&	&	CC	O
CDK2	CDK2	NNP	O
molecular	molecular	JJ	O
dynamics	dynamic	NNS	O
,	,	,	O
the	the	DT	O
residues	residue	NNS	O
Lys129	lys129	CD	O
and	and	CC	O
Glu81	Glu81	NNP	O
formed	form	VBD	O
new	new	JJ	O
hydrogen	hydrogen	NN	O
bonds	bond	NNS	O
interaction	interaction	NN	O
with	with	IN	O
the	the	DT	O
compound	compound	NN	O
in	in	IN	O
pocket	pocket	NN	O
.	.	.	O

The	the	DT	O
nitryl	nitryl	NNP	O
and	and	CC	O
benzoxazole	benzoxazole	NNP	O
scaffold	scaffold	NNP	O
of	of	IN	O
the	the	DT	O
compound	compound	NN	O
3	3	CD	O
formed	form	VBD	O
many	many	JJ	O
important	important	JJ	O
aromatic	aromatic	JJ	O
interactions	interaction	NNS	O
that	that	WDT	O
can	can	MD	O
stabilise	stabilise	VB	O
the	the	DT	O
ligand	ligand	NN	O
-	-	HYPH	O
receptor	receptor	NN	O
complex	complex	NN	O
.	.	.	O

The	the	DT	O
binding	bind	VBG	O
mode	mode	NN	O
of	of	IN	O
the	the	DT	O
different	different	JJ	O
stage	stage	NN	O
revealed	reveal	VBD	O
that	that	IN	O
the	the	DT	O
stabilisation	stabilisation	NN	O
of	of	IN	O
two	two	CD	O
compounds	compound	NNS	O
with	with	IN	O
the	the	DT	O
novel	novel	JJ	O
scaffold	scaffold	NN	O
is	be	VBZ	O
due	due	JJ	O
to	to	IN	O
the	the	DT	O
formation	formation	NN	O
of	of	IN	O
hydrogen	hydrogen	NN	O
bonds	bond	NNS	O
interaction	interaction	NNP	O
,	,	,	O
which	which	WDT	O
was	be	VBD	O
similar	similar	JJ	O
to	to	IN	O
the	the	DT	O
existing	exist	VBG	O
CDK2	CDK2	NNP	O
inhibitors	inhibitor	NNS	O
.	.	.	O

The	the	DT	O
interaction	interaction	NN	O
between	between	IN	O
the	the	DT	O
compounds	compound	NNS	O
and	and	CC	O
the	the	DT	O
amino	amino	JJ	O
acid	acid	NN	O
residues	residue	NNS	O
in	in	IN	O
the	the	DT	O
CDK2	CDK2	NNP	O
active	active	JJ	O
pockets	pocket	NNS	O
during	during	IN	O
the	the	DT	O
molecular	molecular	JJ	O
dynamics	dynamic	NNS	O
simulation	simulation	NN	O
Compound	Compound	NNP	O
1	1	CD	O
in	in	IN	O
0âns	0âns	CD	O
and	and	CC	O
5âns	5âns	CD	O
was	be	VBD	O
showed	show	VBN	O
in	in	IN	O
,	,	,	O
Compound	Compound	NNP	O
3	3	CD	O
in	in	IN	O
0âns	0âns	CD	O
and	and	CC	O
5âns	5âns	CD	O
was	be	VBD	O
showed	show	VBN	O
in	in	IN	O
.	.	.	O

The	the	DT	O
inhibition	inhibition	NN	O
of	of	IN	O
CDK2	CDK2	NNP	O
and	and	CC	O
CDK4	CDK4	NNP	O
kinase	kinase	VBD	O
by	by	IN	O
Compound	Compound	NNP	O
1	1	CD	O
and	and	CC	O
Compound	Compound	NNP	O
3	3	CD	O
was	be	VBD	O
determined	determine	VBN	O
by	by	IN	O
the	the	DT	O
chemiluminescence	chemiluminescence	NN	O
method	method	NN	O
,	,	,	O
and	and	CC	O
Milciclib	Milciclib	NNP	O
was	be	VBD	O
used	use	VBN	O
as	as	IN	O
a	a	DT	O
positive	positive	JJ	O
control	control	NN	O
.	.	.	O

The	the	DT	O
inhibitory	inhibitory	JJ	O
effects	effect	NNS	O
of	of	IN	O
Compound	Compound	NNP	O
1	1	CD	O
and	and	CC	O
Compound	Compound	NNP	O
3	3	CD	O
on	on	IN	O
CDK2	CDK2	NNP	O
were	be	VBD	O
comparable	comparable	JJ	O
to	to	IN	O
those	those	DT	O
of	of	IN	O
the	the	DT	O
positive	positive	JJ	O
drug	drug	NN	O
,	,	,	O
and	and	CC	O
both	both	DT	O
of	of	IN	O
the	the	DT	O
two	two	CD	O
hits	hit	NNS	O
showed	show	VBD	O
significant	significant	JJ	O
selectivity	selectivity	NN	O
.	.	.	O

The	the	DT	O
above	above	JJ	O
results	result	NNS	O
were	be	VBD	O
consistent	consistent	JJ	O
with	with	IN	O
the	the	DT	O
molecular	molecular	JJ	O
dynamics	dynamic	NNS	O
results	result	NNS	O
.	.	.	O

It	-PRON-	PRP	O
also	also	RB	O
indicated	indicate	VBD	O
that	that	IN	O
the	the	DT	O
multistage	multistage	NN	O
virtual	virtual	JJ	O
screening	screening	NN	O
method	method	NN	O
based	base	VBN	O
on	on	IN	O
SVM	SVM	NNP	O
was	be	VBD	O
applicable	applicable	JJ	O
to	to	TO	O
screen	screen	VB	O
for	for	IN	O
the	the	DT	O
compounds	compound	NNS	O
with	with	IN	O
selective	selective	JJ	O
CDK2	CDK2	NNP	O
inhibitory	inhibitory	NN	O
activity	activity	NN	O
.	.	.	O

The	the	DT	O
CDKs	cdk	NNS	O
inhibition	inhibition	NN	O
activity	activity	NN	O
of	of	IN	O
Milciclib	Milciclib	NNP	O
and	and	CC	O
two	two	CD	O
hit	hit	VBN	O
compoundsThe	compoundsThe	NNP	O
proliferation	proliferation	NN	O
experiment	experiment	NN	O
of	of	IN	O
Compound	Compound	NNP	O
1	1	CD	O
and	and	CC	O
Compound	Compound	NNP	O
3	3	CD	O
against	against	IN	O
HCT116	HCT116	NNP	O
and	and	CC	O
A549	A549	NNP	O
was	be	VBD	O
also	also	RB	O
carried	carry	VBN	O
out	out	RP	O
.	.	.	O

Compound	Compound	NNP	O
1	1	CD	O
showed	show	VBD	O
preferable	preferable	JJ	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
against	against	IN	O
both	both	CC	O
HCT116	HCT116	NNP	O
and	and	CC	O
A549	A549	NNP	O
,	,	,	O
especially	especially	RB	O
against	against	IN	O
HCT116	HCT116	NNP	O
with	with	IN	O
IC50	IC50	NNP	O
value	value	NN	O
of	of	IN	O
7.2âÂ±â1.4	7.2ââ±â1.4	CD	O
,	,	,	O
which	which	WDT	O
was	be	VBD	O
equivalent	equivalent	JJ	O
to	to	IN	O
the	the	DT	O
positive	positive	JJ	O
drug	drug	NN	O
Milciclib	Milciclib	NNP	O
,	,	,	O
while	while	IN	O
Compound	Compound	NNP	O
3	3	CD	O
only	only	RB	O
showed	show	VBD	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
against	against	IN	O
HCT116	HCT116	NNP	O
.	.	.	O

Besides	besides	RB	O
,	,	,	O
the	the	DT	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
was	be	VBD	O
not	not	RB	O
as	as	RB	O
good	good	JJ	O
as	as	IN	O
that	that	DT	O
of	of	IN	O
Compound	Compound	NNP	O
1	1	CD	O
.	.	.	O

Comparing	compare	VBG	O
the	the	DT	O
structural	structural	JJ	O
characteristics	characteristic	NNS	O
of	of	IN	O
the	the	DT	O
two	two	CD	O
compounds	compound	NNS	O
,	,	,	O
it	-PRON-	PRP	O
was	be	VBD	O
found	find	VBN	O
that	that	IN	O
Compound	Compound	NNP	O
3	3	CD	O
contained	contain	VBD	O
a	a	DT	O
nitro	nitro	JJ	O
group	group	NN	O
.	.	.	O

The	the	DT	O
group	group	NN	O
possessed	possess	VBD	O
strong	strong	JJ	O
polarity	polarity	NN	O
,	,	,	O
its	-PRON-	PRP$	O
introduction	introduction	NN	O
made	make	VBD	O
it	-PRON-	PRP	O
difficult	difficult	JJ	O
for	for	IN	O
small	small	JJ	O
molecules	molecule	NNS	O
to	to	TO	O
penetrate	penetrate	VB	O
the	the	DT	O
cell	cell	NN	O
membrane	membrane	NN	O
.	.	.	O

This	this	DT	O
might	may	MD	O
be	be	VB	O
the	the	DT	O
reason	reason	NN	O
that	that	IN	O
two	two	CD	O
compounds	compound	NNS	O
with	with	IN	O
similar	similar	JJ	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
at	at	IN	O
the	the	DT	O
protein	protein	NN	O
level	level	NN	O
differ	differ	VBP	O
greatly	greatly	RB	O
at	at	IN	O
the	the	DT	O
cell	cell	NN	O
level	level	NN	O
.	.	.	O

A	a	DT	O
multistage	multistage	NN	O
virtual	virtual	JJ	O
screening	screening	NN	O
method	method	NN	O
combined	combine	VBN	O
by	by	IN	O
SVM	SVM	NNP	O
,	,	,	O
pharmacophore	pharmacophore	NN	O
,	,	,	O
and	and	CC	O
docking	docking	NN	O
method	method	NN	O
was	be	VBD	O
utilised	utilise	VBN	O
for	for	IN	O
screening	screen	VBG	O
the	the	DT	O
CDK2	CDK2	NNP	O
inhibitors	inhibitor	NNS	O
from	from	IN	O
the	the	DT	O
NCI	NCI	NNP	O
database	database	NN	O
.	.	.	O

Initially	initially	RB	O
,	,	,	O
the	the	DT	O
SVM	SVM	NNP	O
,	,	,	O
pharmacophore	pharmacophore	NN	O
,	,	,	O
and	and	CC	O
docking	docking	NN	O
methods	method	NNS	O
were	be	VBD	O
evaluated	evaluate	VBN	O
and	and	CC	O
optimised	optimise	VBN	O
individually	individually	RB	O
with	with	IN	O
the	the	DT	O
training	training	NN	O
and	and	CC	O
test	test	NN	O
set	set	NN	O
constructed	construct	VBN	O
by	by	IN	O
the	the	DT	O
BindingDB	BindingDB	NNP	O
,	,	,	O
Pubchem	Pubchem	NNP	O
,	,	,	O
and	and	CC	O
NCI	NCI	NNP	O
database	database	NN	O
.	.	.	O

After	after	IN	O
optimising	optimise	VBG	O
and	and	CC	O
selecting	select	VBG	O
the	the	DT	O
parameter	parameter	NN	O
and	and	CC	O
function	function	NN	O
score	score	NN	O
of	of	IN	O
docking	docking	NN	O
method	method	NN	O
,	,	,	O
the	the	DT	O
multistage	multistage	NN	O
virtual	virtual	JJ	O
screening	screening	NN	O
method	method	NN	O
with	with	IN	O
SVM	SVM	NNP	O
as	as	IN	O
the	the	DT	O
first	first	JJ	O
filter	filter	NN	O
,	,	,	O
pharmacophore	pharmacophore	NN	O
as	as	IN	O
the	the	DT	O
second	second	JJ	O
filter	filter	NN	O
and	and	CC	O
docking	docking	NN	O
as	as	IN	O
the	the	DT	O
last	last	JJ	O
filter	filter	NN	O
was	be	VBD	O
established	establish	VBN	O
.	.	.	O

The	the	DT	O
validation	validation	NN	O
set	set	NN	O
was	be	VBD	O
applied	apply	VBN	O
for	for	IN	O
evaluating	evaluate	VBG	O
the	the	DT	O
performance	performance	NN	O
of	of	IN	O
this	this	DT	O
multistage	multistage	NN	O
method	method	NN	O
,	,	,	O
the	the	DT	O
values	value	NNS	O
of	of	IN	O
hit	hit	VBN	O
-	-	HYPH	O
rate	rate	NN	O
and	and	CC	O
enrichment	enrichment	NN	O
were	be	VBD	O
higher	high	JJR	O
than	than	IN	O
any	any	DT	O
other	other	JJ	O
methods	method	NNS	O
used	use	VBN	O
alone	alone	RB	O
.	.	.	O

Then	then	RB	O
this	this	DT	O
multistage	multistage	NN	O
virtual	virtual	JJ	O
screening	screening	NN	O
method	method	NN	O
screened	screen	VBD	O
6	6	CD	O
compounds	compound	NNS	O
for	for	IN	O
further	further	JJ	O
molecular	molecular	JJ	O
dynamics	dynamic	NNS	O
,	,	,	O
the	the	DT	O
result	result	NN	O
showed	show	VBD	O
that	that	IN	O
Compound	Compound	NNP	O
1	1	CD	O
and	and	CC	O
Compound	Compound	NNP	O
3	3	CD	O
were	be	VBD	O
stable	stable	JJ	O
in	in	IN	O
the	the	DT	O
ATP	atp	NN	O
-	-	HYPH	O
binding	bind	VBG	O
site	site	NN	O
and	and	CC	O
exhibited	exhibit	VBD	O
similar	similar	JJ	O
binding	binding	NN	O
modes	mode	NNS	O
to	to	IN	O
the	the	DT	O
existing	exist	VBG	O
CDK2	CDK2	NNP	O
inhibitors	inhibitor	NNS	O
.	.	.	O

Finally	finally	RB	O
,	,	,	O
we	-PRON-	PRP	O
used	use	VBD	O
ADP	ADP	NNP	O
-	-	HYPH	O
Glo	Glo	NNP	O
luminescence	luminescence	NN	O
to	to	TO	O
detect	detect	VB	O
the	the	DT	O
inhibitory	inhibitory	JJ	O
effect	effect	NN	O
of	of	IN	O
the	the	DT	O
hit	hit	VBN	O
compounds	compound	NNS	O
on	on	IN	O
CDK2	CDK2	NNP	O
in	in	IN	O
a	a	DT	O
cell	cell	NN	O
-	-	HYPH	O
free	free	JJ	O
system	system	NN	O
.	.	.	O

The	the	DT	O
result	result	NN	O
showed	show	VBD	O
that	that	IN	O
the	the	DT	O
compounds	compound	NNS	O
have	have	VBP	O
good	good	JJ	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
and	and	CC	O
selectivity	selectivity	NN	O
against	against	IN	O
CDK2	CDK2	NNP	O
.	.	.	O

Our	-PRON-	PRP$	O
study	study	NN	O
proved	prove	VBD	O
that	that	IN	O
the	the	DT	O
multistage	multistage	NN	O
virtual	virtual	JJ	O
screening	screening	NN	O
method	method	NN	O
combined	combine	VBN	O
by	by	IN	O
SVM	SVM	NNP	O
,	,	,	O
pharmacophore	pharmacophore	NN	O
,	,	,	O
and	and	CC	O
docking	docking	NN	O
methods	method	NNS	O
was	be	VBD	O
able	able	JJ	O
to	to	TO	O
screen	screen	VB	O
out	out	RP	O
compounds	compound	NNS	O
with	with	IN	O
potential	potential	NN	O
as	as	IN	O
selective	selective	JJ	O
CDK2	CDK2	NNP	O
inhibitors	inhibitor	NNS	O
.	.	.	O

Moreover	moreover	RB	O
,	,	,	O
the	the	DT	O
further	further	JJ	O
inÂ	inÂ	NNP	O
vitro	vitro	FW	O
and	and	CC	O
inÂ	inÂ	NNP	O
vivo	vivo	NN	O
experiments	experiment	NNS	O
and	and	CC	O
structural	structural	JJ	O
modification	modification	NN	O
of	of	IN	O
these	these	DT	O
two	two	CD	O
compounds	compound	NNS	O
will	will	MD	O
be	be	VB	O
carried	carry	VBN	O
out	out	RP	O
for	for	IN	O
investigating	investigate	VBG	O
the	the	DT	O
mechanism	mechanism	NN	O
and	and	CC	O
structure	structure	NN	O
-	-	HYPH	O
function	function	NN	O
relationship	relationship	NN	O
of	of	IN	O
the	the	DT	O
two	two	CD	O
novel	novel	JJ	O
scaffolds	scaffold	NNS	O
and	and	CC	O
designing	design	VBG	O
novel	novel	JJ	O
selective	selective	JJ	O
CDK2	CDK2	NNP	O
inhibitors	inhibitor	NNS	O
.	.	.	O

